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BASP1 is a multifunctional protein which has been found to regulate transcription in 
several different cell lines through acting as a co-factor for WT1 or ERα. BASP1 has 
been reported to possess either tumour suppressor or tumour promoting activity in 
multiple cancer types across multiple tissues. In breast cancer cells, BASP1 acts as 
a tumour suppressor and enhances the effects of tamoxifen treatment. Tamoxifen is 
an ER modulator commonly used to treat breast cancer but long term treatment is 
strongly associated with increased risk of endometrial cancer occurrence. Although 
tamoxifen acts as an ER antagonist in the breast, in the endometrium, tamoxifen 
acts as an ER agonist. 
This study investigated the expression and functions of BASP1 in Ishikawa 
endometrial cancer cells, as well as its effects on tamoxifen action. After confirming 
the presence of endogenous BASP1 in Ishikawa cells, cell line derivatives were 
generated that either knock down or overexpress BASP1. These cells were used to 
determine how BASP1 regulates cell growth, tumourigenicity and transcription of ER 
target genes. BASP1 was found to be primarily cytoplasmic in Ishikawa cells but still 
affected the transcription of a subset of ERα target genes. BASP1 was also found to 
reduce proliferation and colony formation efficiency in Ishikawa cells, indicating 
tumour suppressor activity. qPCR analysis revealed that BASP1 enhances the 
effects of tamoxifen treatment on the expression of a subset of ERα target genes: 
PGR, Greb1 and TFF1.  
The tumour suppressor activity of BASP1 in Ishikawa cells and the modulation of 
tamoxifen action is similar to that which was reported in breast cancer cells. 
However, in Ishikawa cells, BASP1 targeted a different set of ER target genes. The 
work presented here suggests that BASP1 may play a role in the differential effects 
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Brain acid soluble protein 1 (BASP1) is a multifunctional protein found in 
many different tissues and cell types throughout the human body. The RNA and 
protein expression levels of BASP1 are particularly high in the brain and are found 
across a vast array of cell types within multiple areas of the brain including neuronal 
cells and glial cells of the cerebral cortex, hippocampus and caudate, endothelial 
cells and neuropils of the cerebral cortex and cells of both the granular layer and the 
molecular layer of the cerebellum (1). BASP1 was first characterised in the axonal 
termini of neuronal cells as a member of the GAP-43 family, a group of proteins 
which were known to be involved in axon growth and memory formation (2) However, 
BASP1 has since been identified in a vast array of different organs, tissues and cell 
types throughout the body including but not limited to those of the endocrine tissues, 
bone marrow, lungs, stomach, kidneys and skin, as well as both male and female 
reproductive tissues (1).  Depending on the cell type and location, BASP1 has been 
proposed to perform a range of different context specific activities and functions (3). 
 
1.1.2 BASP1 structure 
The primary structure of BASP1 is highly conserved between species and in 
most cases BASP1 knockdown is lethal in animal models (4). Notable structural 
motifs of BASP1 are its PEST sequences, phosphorylation sites, nuclear localisation 





Figure 1 - Structure of human BASP1 
Notable regions are denoted by: MM (Myristoylation motif), NLS (Nuclear Localisation 
Sequence), P-site (phosphorylation sites) and PEST (PEST motifs). Residue number is 
indicated by a scale above the diagram. Many more phosphorylation sites have now been 
proposed but only the four most referenced sites were included (8). 
 
PEST motifs are regions of protein rich in proline, glutamic acid, serine and threonine 
that are strongly associated with a fast protein turnover rate (5). The multiple 
phosphorylation sites can be targeted by protein kinases such as protein kinase C 
(PKC) which can affect BASP1 activity and membrane binding capability (7). The N-
terminal myristoylation motif allows BASP1 to anchor to lipid membranes with some 
specificity for certain lipids such as neutral phosphatidylcholine (6). Once bound to 
the membrane, BASP1 is able to modify the lipid makeup of the membrane in close 
proximity by accumulating cholesterol at the site, in some cases to such an extent 
that cholesterol crystals can form (9, 10). The N-terminal myristoyl motif provides 
BASP1 with some hydrophobic character, despite it being a mostly hydrophilic 
protein (5). N-terminal myristoylation of this motif is required for many of BASP1s 
functions (11, 12). 
 
1.1.3 BASP1 functions 
BASP1 can have many different functions depending on the tissue 
environment, cell type and presence of other cofactors and transcription factors. 
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Within neurones, BASP1 has been proposed to have a range of functions that 
include involvement with synaptic signal transmission, neuronal signal transduction, 
neurite growth, regeneration and memory formation.  BASP1 can affect 
neurotransmitter signalling by interacting with calcium bound calmodulin and PKC in 
the membranes of synaptic vesicles (13). In addition, BASP1 has been shown to 
form cation selective ion channels in lipid bilayers which affects membrane 
conductance in neurones (14). BASP1 has also been shown to be upregulated 
following multiple forms of nerve injury in several neurone subtypes and this 
upregulation is associated with neurone regeneration (15). Increased expression of 
BASP1 has also been shown to promote both NCAM (neural cell adhesion molecule) 
independent neurite outgrowth and nerve sprouting. This is an essential process in 
the development of proper brain structure, particularly in the later stages of 
development, and has implications for the potential roles of BASP1 in determining 
neurone plasticity and memory formation (11). This process is an example of BASP1 
activity which is dependent on N-terminal myristoylation of BASP1 (see section 
1.1.2). 
It is now known that BASP1 likely has additional functions in other cell types. 
BASP1 has been shown, in the presence of WT1(Wilms tumour 1), to be  capable of 
altering K562 myelogenous leukaemia cell’s differentiation pathway to produce cells 
with neurone like morphology (16). BASP1 also likely has roles in the development of 
other tissues, such as the kidneys. BASP1 is expressed during kidney nephrogenesis 
and continues to be expressed into adulthood, with expression being limited to the 
podocyte cells (17). This expression pattern seen in kidney development is shared by 
the transcription factor WT1 that is essential for proper kidney development (18). 
Other functions of BASP1 that have been proposed include the modulation of myc in 







WT1 is a zinc finger protein that is essential for the development of multiple different 
mammalian tissues including the mesothelium, gonads, heart, blood vessels, blood, 
spleen, nervous system, eyes, lungs, liver and kidneys (21-23). In humans WT1 is 
highly expressed in the spleen, smooth muscle and kidney as well as both male and 
female reproductive systems (24). Similar to BASP1, WT1 can exhibit a range of 
different activities and functions, in part due to the alternative splicing of the WT1 
gene. The four main splice variants of WT1 arise because of the presence or 
absence of an additional 17 amino acid sequence encoded by exon 5 (between the 
N-terminus and the zinc finger domains) and a possible 3 amino acid insertion of 
lysine, threonine and serine in exon 9 (between the third and fourth zinc fingers 
domain) called KTS (25) (fig.2).  
 
1.2.2 WT1 structure 
WT1 can bind to target DNA using its c-terminal zinc finger motifs in order to 
modulate transcription. WT1 zinc finger motifs are also able to bind to RNA which 
could potentially result in altered alternative splicing or translation of the targets. 
These activities are controlled by repression and activation domains in the N-terminal 
and central regions of the protein (26). Transcriptional co-modulators such as BASP1 





Figure 2 - Structure of human WT1 
Notable regions are denoted by: RD (repression domain), AD (activation domain), 17AA (17 
amino acid splice variation site), ZF (zinc finger motifs) and KTS (KTS slice variation site). 
Residue number is indicated by a scale above the diagram. 
 
1.2.3 BASP1-WT1 interaction 
 
In human embryonic kidney (HEK) cells, BASP1 was shown to translocate to 
the nucleus where it regulates WT1 to exert its effect on WT1 target genes (17). The 
mechanism of transcriptional regulation by BASP1 involves the recruitment of a large 
protein complex. BASP1’s nuclear localisation sequence (NLS) allows it to 
translocate to the nucleus where it binds to WT1 at the promoters of WT1 target 
genes (17).  
 
Figure 3 - BASP1 acting as a transcriptional co-suppressor for WT1. 
a) WT1 (Wilms tumour 1) binds to target genes and recruits CBP (CREB binding protein), 
resulting in histone acetylation and activation of transcription. b) BASP1 binding to WT1 
results in the dissociation of CBP and the recruitment of HDAC1 (Histone Deacetylase) 




The N-terminal myristoyl group of myristoylated BASP1 allows the recruitment 
of phosphatidylinositol 4,5 bisphosphate (PIP2) to the BASP1-WT1 complex located 
at the WT1 target gene promoter (fig.3). BASP1 binding of PIP2 in turn allows the 
recruitment of histone deacetylase 1 (HDAC1) (12). HDAC1 is a histone remodelling 
factor that removes the acetyl side chain from a histone lysine residue (H3K9) 
resulting in chromatin condensation. The recruitment of HDAC1 to a WT1 target gene 
results in local condensation of chromatin and thus transcriptional repression of the 
target (fig.3b). BASP1 is also able to recruit prohibitin, another transcriptional co-
repressor. Prohibitin, in turn, recruits ATP dependent chromatin remodelling factors 
such as brahma related gene 1 (BRG1) which results in the dissociation of CREB 
binding protein (CBP) from the promoter (27). CBP has histone acetyl transferase 
activity (results in relaxation of chromatin structure) and is a scaffold protein for the 
transcriptional complex (28). The dissociation of CBP therefore results in further 
transcriptional repression of WT1 target genes. BASP1 is therefore able to convert 
WT1 activity from a transcriptional activator to a transcriptional repressor of WT1 











1.3 BASP1 and WT1 in Cancer 
 
1.3.1 WT1 in embryonal cancers 
WT1 is involved in the formation and progression of many different solid tumours and 
leukaemias, either as an oncogene or a tumour suppressor gene. WT1 dependent 
tumours can be broadly divided into two groups: embryonal and adult. The most well 
documented WT1 dependent embryonal tumour is the Wilms Tumour. WT1 loss of 
function mutations are some of the highest frequency mutations found in Wilms 
tumour (nephroblastoma) (29). This tumour commonly develops in patients with 
WAGR syndrome (Wilms tumour- Aniridia- Genitourinary abnormalities- mental 
Retardation) in which the WT1 gene is deleted (30). Wilms tumour is also commonly 
found in patients with Denys Drash Syndrome (DDS) due to a high frequency of 
mutation in the DNA binding domain of the WT1 gene (31). Another tumour shown to 
be embryonal in origin is desmoplastic small round cell tumour (32). WT1 is also 
frequently mutated in DSCRT of the abdomen. This solid tumour can be caused by a 
reciprocal translocation that results in the formation of and, unlike in Wilms tumour, 
overexpression of an EWS-WT1 fusion protein (33). In this cancer type, WT1 acts as 
a tumour suppressor which can be silenced by mutation but this is not the case in all 
cancer types.  
 
1.3.2 WT1 in adult cancers 
Leukaemias, melanomas and breast cancers are all examples of adult cancers 
which, in some cases, can be WT1 dependent. In adult cancers in which WT1 is 
implicated, WT1 often exhibits oncogenic activity. WT1 can even be found to be 
expressed in adult cancers of tissues in which WT1 would not normally be 
expressed. Adult cancers which have been found to be WT1 dependent in some 
cases include leukaemias, melanomas, renal cancers and breast cancers (34-36). 
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WT1 is overexpressed in as many as 80% of cases of some subsets of leukaemia 
which indicates that WT1 can also have oncogenic activity (35). In addition, WT1 
mutations can also be associated with poor prognosis such as in both adult and 
childhood cases of acute myelogenous leukaemia (AML) (37, 38). WT1 therefore is a 
highly complex, context specific transcription factor with multiple different functions 
and mutations in different cancer types. WT1 has even been found to be 
overexpressed in some leukaemia cases and have loss of function mutations in 
others (35, 39). 
 
1.3.3 BASP1 in cancer 
Unsurprisingly, BASP1 too has multiple different functions, activities and 
mutations in a variety of different cancer types. BASP1 has been shown to exhibit 
various tumour suppressive activities in acute myelogenous leukaemia cell lines 
including proliferation inhibition and increased apoptosis. In addition, BASP1 
promoter DNA methylation and silencing by the AML1-ETO fusion protein has been 
observed in AML cells (40). As WT1 is overexpressed in many cases of AML it is 
possible that BASP1 exerts its tumour suppressor activity by co-repression of WT1 
target genes. Similarly, BASP1 has been shown to be downregulated by DNA 
methylation in some hepatocellular carcinoma cases (41). BASP1 has also been 
shown to have reduced expression in thyroid cancer cells compared with normal 
tissue, and restoration of BASP1 resulted in inhibition of cell growth and migration 
(42). These reports show that BASP1 can act as a tumour suppressor in multiple 
cancer types and is often a target of repression in cancer cells. However, one 
exception has been demonstrated in cervical cancer cells. BASP1 expression was 
shown to promote cancer cell proliferation, colony formation efficiency and 
tumourigenicity as well as being associated with increased stage progression and 




1.3.4 BASP1 in breast cancer 
The effects of BASP1 expression on breast cancer cells has also been 
investigated and the results indicated that, in this cell type, BASP1 acts as a tumour 
suppressor (44). In addition to exhibiting tumour suppressor activity, BASP1 
expression has been associated with increased breast cancer patient survival. 
Interestingly, BASP1 was also found to colocalise with several components of the 
nuclear actin network including β-actin, gelsolin, myosin-1C (MYO1C) and flightless 1 
(FLI1). These nuclear actin network proteins are known to interact with ERα, the 
hyper proliferative hormone receptor protein target of the breast cancer drug 
tamoxifen (45). In the same study, BASP1-ERα colocalisation was then observed 
and it was shown that BASP1 colocalises with ERα in the nucleus, suggesting 
BASP1 as an ERα cofactor. Subsequent investigation of the effect of BASP1 
expression on tamoxifen action was conducted and it was shown that 40% of the 
genes regulated by tamoxifen in MCF7 cells were BASP1 dependent. BASP1 
expression was also found to enhance the inhibitory effects of tamoxifen on cell 
proliferation and colony formation (44). 
The effects of BASP1 expression on specific genes associated with tamoxifen 
resistance were also investigated. BASP1 was found to affect tamoxifen induced 
gene expression changes in several genes associated with tamoxifen resistance, 
including DLC1, BMPER, SOX2, XBP1, Rab31 and Serpina3 (44). These results 
together indicated that BASP1 plays a major role in tamoxifen response in breast 







1.4 Tamoxifen and the ER 
 
1.4.1 Tamoxifen 
Tamoxifen is a non-steroidal selective estrogen receptor modulator (SERM) 
used to treat ER+ breast cancers, which make up approximately 70% of all human 
breast cancer cases (46, 47). Tamoxifen can be used to treat either primary or 
secondary breast cancer cases in both females and males. In some cases tamoxifen 
can also be used to treat progesterone receptor positive (PR+) ER- breast cancer, 
which is extremely rare, and ductal carcinoma in situ (DCIS), which makes up 
approximately 12% of breast cancer cases, but  tamoxifen treatment for these 
conditions is less effective (48, 49). Tamoxifen has also been shown to reduce the 
incidence of invasive and non-invasive breast cancer recurrence and breast cancer 
occurrence in high risk individuals. It can therefore be administered as a preventative 
treatment for patients with a high incidence of breast cancer occurrence in their 
family (50, 51). Tamoxifen is a cytostatic drug that exerts its anti-proliferative effect 
on breast cancer cells by acting as an ER antagonist (52). This inhibits estrogen 
signalling and thus reduces the hyper-proliferative activity of ERα. As a prodrug, 
Tamoxifen is administered orally and then is metabolised in the liver into its active 
forms, N-desmethyl-tamoxifen and 4-hydroxytamoxifen, by cytochrome p450 
enzymes (53). N-desmethyl-tamoxifen is the most readily produced metabolite of 
tamoxifen but 4-hydroxy-tamoxifen is often studied due to its greater anti-estrogenic 
activity (54).   
 
1.4.2 ER 
Estrogen receptors are nuclear receptors that are essential for the proper 
development of many organs including the uterus, ovary, mammary gland, prostate, 
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lungs and brain (55). Notable structural components of ER are its DNA binding 
domain, hinge region, ligand binding domain and two activation functions (fig.4).  
 
 
Figure 4 - Structure of human ERα 
Notable regions are denoted by: AF-1 (Activation Function 1), DBD (DNA binding domain), 
HD (Hinge region), and LBD (Ligand Binding Domain). Residue number is indicated by a 
scale above the diagram. 
 
The DNA binding domain (DBD), located in the centre of the protein, contains 
two zinc finger motifs and is responsible for recognition and binding of specific DNA 
sequences (56). The hinge region connects the DBD and ligand binding domains and 
contains a nuclear localisation sequence (NLS) for nuclear translocation (57). The 
two activation domains are found in the N-terminus (AF-1) and the ligand binding 
domain (AF-2) and are responsible for the recruitment of transcriptional co-regulators 
to determine activity (58). AF-1 is a ligand independent constitutively active domain 
while AF-2 depends on ligand binding for its activation. AF-2 is found in the C-
terminal ligand binding domain (LBD), which is responsible for the binding of ligands 
such as estrogens and coactivators, as well as ER dimerization (59). ERs can be 
divided into two groups: ERαs and ERβs. The DBDs of the two groups are highly 
conserved, meaning that their DNA binding affinity and specificity is very similar, but 




1.4.3 ER activation 
ERs can be activated by several different mechanisms, some ligand 
dependent and some ligand independent. The ligand dependent pathways of ER 
activation require ligands such as estrogens to bind to the AF-2 in the ligand binding 
domain of the receptors while the ligand independent pathways require kinases, 
activated by growth factors, to phosphorylate the ER. The most prevalent estrogen in 
humans is estradiol (E2). In the ligand dependent mechanism of ER activation, a 
ligand binds to the LBD of the ER, resulting in a conformational change and 
dissociation of chaperones and other binding proteins from the ER (61). This allows 
the ER to dimerise and translocate in to the nucleus where it exerts its effects on 
transcription (62). The ligand independent pathways of ER activation do not require 
estrogenic compounds but instead require phosphorylation of the ER. This 
phosphorylation of ERs can be induced by several different pathways including those 
of protein kinases (PKA/PKC), growth factor signalling or cyclin dependent kinases 
(63-66). Phosphorylation at various sites within the ER can increase dimerization and 
cofactor interaction to allow translocation to the nucleus and transcriptional regulation 
of target genes (58).  
 
1.4.4 ER mechanisms of action 
In addition to having multiple mechanisms of activation, ERs have multiple 
mechanisms of function as well. These can be divided into three main groups. The 
first and most well studied ER mechanism of activity is the classical pathway (fig.6a), 
in which ER dimers in the nucleus bind to specific DNA sequences called estrogen 
response elements (EREs) (58). Once bound, ER recruits a complex of coactivators, 
including chromatin remodelling factors such as steroid receptor coactivators (SRCs) 





Figure 5 –ERα co-repressor and co-activator complexes 
a) ERα (Estrogen Receptor α) binds to target genes and recruits NCoR-2 (Nuclear co-
repressor 2), which results in recruitment of corepressors such as HDAC (Histone 
Deacetylase) to repress transcription. b) Ligand bound ERα recruits SRC1 via its LLXXL motif 
in the AF-2 region. SRC1 recruitment results in the recruitment of coactivators such as CBP 
(CREB Binding Protein) to acetylate histones and activate transcription. 
 
The second mechanism of ER activity is that of ERE independent genomic action. 
Similarly to the classical pathways, ER must first dimerise and translocate to the 
nucleus, but instead of binding directly to DNA via EREs, ER binds indirectly to gene 
promoters by interacting with other transcription factors (fig.6b) (68). This allows the 
ER to affect transcription of genes that do not contain EREs. The third and final 
mechanism is that of non-genomic action. In this mechanism, ligand bound ER 
outside the nucleus produces kinase signalling cascades which can affect the activity 
of other transcription factors (fig.6c) or even affect already transcribed and translated 




Figure 6 - Estrogen dependent mechanisms of ERα activity 
Key to the right of the diagram indicates E2 (estradiol), ER (Estrogen receptor) and TF (other 
Transcription Factors). a) E2-ERα dimer enters nucleus and binds to EREs. b) E2-ERα dimer 
enters nucleus and modulates other transcription factors. c) E2-ERα dimer phosphorylates or 
otherwise modifies other transcription factors in the cytoplasm.  
 
1.4.5 Tamoxifen mechanism in breast cancer 
In ER+ breast cancer, in the absence of tamoxifen, estrogen can bind to ERα, 
forming an activated complex that drives proliferation of the cancer cells (70). E2 
binding to ERα results in a conformational change, positioning the twelfth helix (H12) 
of the ERα LBD (fig.3) over the dimerization domain, allowing dimerization and 
nuclear localization (71, 72). This conformation also allows the LBD to bind to 
transcriptional co-activators via the co-activators LXXLL helix, resulting in 
transcriptional activation of target genes (73). Tamoxifen treatment reduces 
proliferation of breast cancer cells by competitively inhibiting E2 from binding to ERα. 
Tamoxifen is similar in structure to E2 and binds to the same region of the ERα LBD, 
similarly inducing a conformational change that permits dimerization and nuclear 
localisation. However, Tamoxifen possesses an additional side chain which prevents 
the proper relocation of H12. H12 is repositioned in such a way that it sterically 
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hinders LXXLL helix binding to the LBD, preventing association of co-activators and 
thus preventing transcriptional activation of target genes (73). Instead, TAM-ERα 
recruits a complex of transcriptional corepressors such as N-CoR (Nuclear Receptor 
Co-Repressor) and SMRT (Silencing Mediator for Retinoid or Thyroid hormone 
receptor) (74). Since tamoxifen binding doesn’t affect DNA binding specificity, this 
mechanism results in inhibited estrogen signalling and the active repression of ERα 
target genes.  
It should be noted that tamoxifen has been shown to also have some ER 
independent activity. In ER- cancer cells tamoxifen has been shown in some cases to 
inhibit protein kinase C (PKC), transforming growth factor β (TGF-β) and cyclin 
dependent kinases (CDKs) either by direct interaction or by enhancing other 
inhibitors (75-77). However, the effects of tamoxifen on ER- breast cancer cells are 
variable and tamoxifen is only very rarely used to treat non ER+ breast cancer 
















1.5 Tamoxifen as an estrogen agonist 
 
1.5.1 Tamoxifen as an estrogen agonist 
One side effect of tamoxifen is an increased risk of endometrial cancer later in 
life. While tamoxifen acts as an ER antagonist in certain tissues such as breast and 
brain tissue, in other tissues such as the uterus, bone and liver tissue tamoxifen acts 
as an ER agonist (78). This estrogenic activity presents a problem for tamoxifen 
treatment of breast cancer because the induction of ER activity in the uterus is a risk 
factor for endometrial cancer formation (79). Estrogen replacement therapies have 
been shown to increase the risk of endometrial cancer and now include progesterone 
treatment to reduce this symptom (80). Long term tamoxifen treatment has similarly 
been strongly associated with increased incidence of endometrial cancer. The 
relative risk of endometrial cancer formation in long term tamoxifen treated patients 
compared with untreated subjects has been shown to increase 1.2-19.4 fold, 
depending on duration of treatment (81). The level of increased risk of endometrial 
cancer formation has also been shown to increase with duration of tamoxifen 
treatment (81). The frequency of endometrial cancer formation, however, is still 
relatively low. The most recent statistics from cancer research UK place frequency of 
endometrial cancer incidence at 0.04-0.1% of the European female population 
depending on age group (82). In tamoxifen treated patients, therefore, this can 
increase to as much as 2%. For this reason, despite the risks, tamoxifen is still used 
to treat the majority of ER+ breast cancer patients because the benefits to survival of 
patients with breast cancer and the reduction in recurrence outweigh the risk of 





1.5.2 Endometrial cancer 
Endometrial cancer is a cancer of the inner epithelial lining of the uterus. This 
lining separates the inner uterine cavity from the myometrium (83). The endometrium 
itself is made up of two layers: the functionalis (adjacent to the uterine cavity) and the 
basalis (adjacent to the myometrium) (83). The functionalis is the hormone 
responsive layer of cells that thickens in response to estrogen and sheds in response 
to progesterone during the menstrual cycle. The basalis effectively forms the base of 
the endometrium and it is from this base that the functionalis regenerates (83). 
Tamoxifen is associated with endometrial cancer formation, tumour stage 
progression and poor prognosis but is still commonly used to treat breast cancer 
because the benefits outweigh the risks (81). Analysis of the mortality rates among 
tamoxifen induced endometrial cancer cases has produced varying results but it is 
now thought that mortality is higher than in non-tamoxifen induced endometrial 
cancer (84).  
 
1.5.3 ER independent endometrium tamoxifen mechanism 
There are many proposed mechanisms for tamoxifen’s effect on endometrial 
carcinogenesis and stage progression but the exact processes are not known for 
certain. This could be, in part, due to the majority of gene expression studies 
investigating the short term effects of tamoxifen treatment, while endometrial cancer 
risk is associated with very long term tamoxifen use. In addition, Tamoxifen appears 
to modulate gene expression in endometrial cells by a multitude of different 
mechanisms, some ER dependent and some ER independent. Substantial crossover 
between tamoxifen and estradiol induced gene expression changes has been 
observed in endometrial cells but tamoxifen is also known to regulate other genes, 
independent of the ER (85).  
33 
 
One proposed mechanism of ER-independent tamoxifen associated 
endometrial carcinogenesis is the increased rate of DNA damage induced by 
tamoxifen treatment. Some tamoxifen metabolites have been shown to form DNA 
adducts but their role in endometrial carcinogenesis has not yet been determined 
(86, 87).  
Another proposed mechanism is alteration of the UPR (Unfolded Protein 
Response) and mTOR (Mammalian Target of Rapamycin) signalling pathways. In 
healthy cells, the UPR pathway activates in order to control apoptosis in response to 
endoplasmic reticulum related stress but this process can often be inappropriately 
activated in breast cancer cells in response to long term endocrine cancer therapy 
(88). In endometrial cells, tamoxifen has been shown to increase expression of BiP 
(Binding Immunoglobulin Protein), an endoplasmic reticulum stress response 
chaperone, which could suggest that the UPR pathway can be over-activated in 
endometrial cells as well (87). In addition, in breast cancer cells, BiP is known to 
regulate expression of mTOR (89) which has also been associated with tamoxifen 
induced endometrial cancer (90).  
Tamoxifen can also modulate the expression of the ER gene but results have 
been highly variable, with some studies indicating an upregulation of ERα in the 
endometrium and others indicating downregulation (81, 91). One isoform of ERα, 
ERα-36, has been shown to be overexpressed in endometrial cancer cells and can 
activate the MAPK/ERK and PI3K/Akt pathways in the presence of tamoxifen. 
Activation of these pathways affects differentiation and apoptosis, as well as reducing 
the control of expression of c-myc, a potent driver of cell proliferation (92). 
1.5.4 ER dependent endometrium tamoxifen mechanism 
In addition to these non-estrogenic mechanisms, tamoxifen is known to 
modulate ER activity in endometrial cells. In breast cancer cells, tamoxifen functions 
34 
 
by acting as an ER antagonist but in endometrial cells tamoxifen acts more as an ER 
agonist. It is not fully understood why tamoxifen acts as an agonist in endometrial 
cells but it has been shown that TAM-ER recruits a very different set of co-
modulators in endometrial cells compared with breast cells. While in breast cells 
TAM-ER recruits co-repressors such as N-CoR and SMRT, in endometrial cells, 
TAM-ER recruits coactivators such as SRC-1 and CBP (93). This co-activator 
complex bears more similarity to that which is recruited by the E2-ER complex in 
breast cells. It is therefore possible that differing expression levels and activities of 
TAM-ER coactivators and corepressors between the two cell types could be 
responsible for some of the opposing effects on the ER.  
 
1.5.5 BASP1 novel ER modulator 
As previously stated, BASP1 and ERα have been shown to co-localise in the 
nucleus of breast cancer cells. It was also shown by RNA sequencing that 40% of the 
genes regulated by tamoxifen were BASP1 dependent. This was then confirmed by 
Chromatin Immuno-precipitation (ChIP) of four of the regulated genes: XBP1, Rab31, 
Serpina3 and PGR. Both BASP1 and ERα were detected at the promoters of these 
ER target genes (44). These results indicated that BASP1 could be a novel ER 
cofactor in breast cancer cells which affects TAM-ER activity. As BASP1 is also 
expressed in the endometrium (1), it is possible that BASP1 functions differently in 
the two cell types which could potentially contribute to the differences in TAM-ER 








1.6 Research aims 
 
BASP1 has recently been shown to act as an ERα cofactor and tumour 
suppressor in breast cancer cells (44). In breast cancer treatment, tamoxifen is often 
used to inhibit the hyper-proliferative effects of ERα (47). While tamoxifen exhibits 
ER antagonist activity in breast cells, it exhibits mostly ER agonist activity in 
endometrial cells (78). BASP1 is normally expressed in the adult endometrium but 
ceases to be expressed in the adult breast after puberty (1, 94). This suggests that 
BASP1 has different functions in the two tissue types. It is also possible that BASP1 
has roles in tamoxifen response in endometrial cells as well as breast cancer cells.  
The aim of this project was to investigate the effects of BASP1 expression in 
endometrial cancer cells. Ishikawa cells, an ER+ endometrial adenocarcinoma cell 
line, were used to produce stable cell lines in which BASP1 expression was 
manipulated. These cell lines were then used to investigate the effects of BASP1 
expression on proliferation, gene expression and response to tamoxifen treatment in 
endometrial cancer cells.  
The first specific objective of the project was to examine the effects of 
changing BASP1 expression on growth and survival of Ishikawa cells. Growth assays 
and colony formation assays using Ishikawa cells were performed to examine 
whether BASP1 possesses tumour suppressor activity in Ishikawa cells. BASP1 has 
been shown previously to possess tumour suppressor activity in breast cancer cells 
(44). Since BASP1 is not normally expressed in adult breast tissue, it is likely that 
BASP1 becomes reactivated upon transformation of the breast cells. The purpose of 
this phenotype investigation is to determine whether BASP1 possesses this same 
tumour suppressor activity in endometrial cancer cells, or whether its functions are 
different, (as the difference in expression between the two adult tissues indicates).  
36 
 
The second specific objective of the project was to examine the effects of 
changing BASP1 expression on Ishikawa cell gene expression. BASP1 has been 
shown to act as a cofactor for transcription factors WT1 and ERα in other tissues (17, 
44).  For this reason, the investigation of BASP1 dependent gene expression 
changes in Ishikawa cells was focused on ERα and WT1 target genes.  
The third and final specific objective of the project was to examine the effects 
of changing BASP1 expression on tamoxifen response in Ishikawa cells. Since 
BASP1 has been shown to modulate approximately 40% of tamoxifen induced gene 
expression changes in breast cancer cells, it was hypothesised that BASP1 could 
possibly be able to modulate tamoxifen induced gene expression changes in 
endometrial cancer cells as well. This was investigated using growth assays, colony 
































The following chemicals and reagents were bought from Sigma Aldrich 
Ishikawa cells, Foetal Bovine Serum (FBS), Phosphate Buffered Saline (PBS), 4OH-
Tamoxifen (TAM), Ethanol, Methanol, Crystal violet, Bovine Serum Albumin (BSA), 
Triton and Paraformaldehyde (PFA). 
The following chemicals were bought from Thermo Fisher Scientific/Gibco 
Phosphate Buffered Saline (PBS), Pierce ECL Western Blotting Substrate, CL-
Xposure film, SYBR green assay reagents, agarose, Tris-Acetate-EDTA (TAE) 
buffer, Dulbecco’s Modified Eagle’s Medium (DMEM), Roswell Park Memorial 
Institute (RPMI) medium, Penicillin Streptomycin (PS), L-Glutamine (LG), spectra BR, 
filter paper, 6X DNA loading dye, LR DNA ladder gene ruler, TWEEN, Tris and 
Ammonium Persulphate (APS).  
The following chemicals were bought from Invitrogen/Ambion 
One-shot top10 chemically competent e-coli, pcDNA3 plasmids, pSilencer plasmids, 
MagG dynabeads, proteinase K and RNase A 
Other products were bought from the following manufacturers 
MCF7 cells and K562 cells were bought from the European Collection of 
Authenticated Cell Cultures (ECACC). Effectene transfection reagent, QIA-prep Spin 
Mini-prep Kit 250, RNeasy kit and QIA-Quick PCR purification kit were from QIAGEN. 
Immobilon-P membranes, NP40 and protease inhibitor cocktail set III were from 
Merck Millipore. Bradford 1X dye reagent, iScript reagents and acryl-bis mix were 
from Bio-Rad. NaCl and ethidium bromide were from VWR Prolabo Chemicals. PCR 
primers were from Integrated DNA technologies (IDT). Other reagents include 
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TEMED (Flowgen Bioscience), MgCl2 (Acros Organics), molecular biology water 
(Pannreac AppliChem), glycine (Promega), and G418 (Melford). 
 
2.1.2 Antibodies 
ERα HC-20 (sc-543) and Lamin A/C (E-1) antibodies were from Santa Cruz 
(Santa Cruz, CA, USA). β-Actin (A5316) antibodies were from Sigma Aldrich (St 
Louis, MO, USA). β-tubulin (10068-I-AP) antibodies were from Protein-tech 
(Manchester, UK). Secondary antibodies, anti-rabbit (32260) and anti-mouse 
(32230), were from Thermo Fisher Scientific (Paisley, UK). WT1 and BASP1 
antibodies were from SAPU (Edinburgh, UK). Normal rabbit IgG antibody (12-370) 














2.2 Solutions and buffers 
 
Blocking buffer: 50mM Tris, 150mM NaCl, 0.05% (v/v) TWEEN, 1% (w/v) BSA. 
Cell signalling lysis buffer: 20mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 
1mM EGTA, 1% (v/v) Triton. 
Cytoplasmic lysis buffer: 10mM Tris-HCl pH8.1, 10mM NaCl, 1.5mM MgCl2, 0.5% 
(v/v) NP40. 
High salt ChIP buffer: 500mM NaCl, 50mM Tris-HCl pH 8.0, 5mM EDTA, 0.5% (v/v) 
NP40, 1% (v/v) Triton X-100. 
LiCl buffer: 10mM Tris-HCl pH 8.0, 250mM LiCl, 1mM EDTA, 1% (v/v) NP40, 1% 
(w/v) sodium deoxycholate. 
Low salt ChIP buffer: 150mM NaCl, 50mM Tris-HCl pH8.0, 5mM EDTA, 0.5% (v/v) 
NP40, 1% (v/v) Triton X-100. 
PK buffer: 125mM Tris-HCl pH 8.0, 10mM EDTA, 150mM NaCl, 1% (w/v) SDS. 
Resolving gel: 375mM Tris pH 8.8, 10% (w/v) acryl/Bis gel mix, 0.1% (w/v) SDS.  
Stacking gel: 125mM Tris pH6.8, 3.75% (w/v) acryl/Bis gel mix, 0.1% (w/v) SDS 
TE buffer: 10mM Tris-HCl pH 8.0, 1mM EDTA. 






2.3 Tissue culture 
 
2.3.1 Ishikawa cells 
Ishikawa cells were bought from Sigma. Ishikawa cells were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) from Gibco (41966-029) with 5% (v/v) 
Foetal Bovine Serum (FBS) (Sigma) and 1% (v/v) Penicillin Streptomycin (PS) 
(Gibco) incubated at 37°c and 5% CO2.  
 
2.3.2 MCF7 cells 
MCF7 cells were bought from the European Collection of Authenticated Cell 
Cultures (ECACC, Salisbury, UK). Stable MCF7 cells used were set up in our 
laboratory by transfection with pSilencer plasmids as detailed previously (44). MCF7 
stable cell lines were grown in DMEM (Gibco) with 10% (v/v) FBS (Sigma), 1% (v/v) 
PS (Gibco) and 700μg.mL-1 G418 from Melford (Ipswich, UK), incubated at 37°c and 
5% CO2. 
 
2.3.3 K-562 cells 
K562 cells were bought from ECACC. Stable K562 cells used were 
established by transfection with pcDNA3 plasmids as detailed previously (17). K562 
stable cell lines were grown in Roswell Park Memorial Institute (RPMI) medium 
(Gibco, 31870-025) with 10% (v/v) FBS (Sigma), 1% (v/v) PS (Gibco) and 1% (v/v) L-




2.4 Stable transfection of Ishikawa cells  
 
2.4.1 E-coli culture 
Liquid LB medium used was prepared in house by the University of Bristol 
media preparation laboratory. Transformation competent E-coli cells were One-shot 
top10 chemically competent e-coli, bought ready to use from Invitrogen (C404006) 
(Carlsbad, CA, USA). 
 
2.4.2 Preparation of DNA  
Stable Ishikawa cell lines were set up using pcDNA3 plasmids (Invitrogen) 
and pSilencer plasmids (5765G) from Ambion (Invitrogen). The B-Ishikawa cell line 
was set up using pcDNA3 plasmids containing a BASP1 expressing region as 
detailed previously (17). The sh-BASP1 cell line was set up using pSilencer plasmids 
containing an sh-RNA expression region which targets BASP1 as detailed previously 
(44). Before transfection, pSilencer plasmids were expanded by transformation of 
competent E. coli cells. Ligation DNA was added at a volume of 3µL to 200µL of 
competent cell E. coli and kept on ice for 30 minutes. Samples were heat shocked at 
42˚C for 2 minutes and after cooling were spread onto 100 µg/mL ampicillin plates 
and incubated at 37˚C overnight. Plasmids were isolated from samples using a QIA-






2.4.3 Ishikawa cell Transfection  
Ishikawa stable cell lines were set up using pcDNA3 (Invitrogen) or pSilencer 
2.1 neo (Ambion) vectors detailed in section 2.4.2. Transfection was conducted using 
QIAGEN effectene transfection reagent. 106 cells were seeded in 10cm plates and 
incubated for 24 hours before treatment with transfection complexes for 48 hours. 
Media was then changed to DMEM (as described in section 2.3.1) with 1mg/mL 





















2.5.1 Western blotting 
Western blots were performed with either whole cell samples or nuclear and 
cytoplasmic fractions mixed with SDS loading dye. For whole cell samples, cells were 
extracted by scraping on ice and harvested by centrifugation at 1400 RCF for 3 
minutes before being re-suspended in PBS (Fisher). The appropriate volume of 
loading dye was added and the samples were then heated to 95°c for 10 minutes. 
Nuclear and cytoplasmic fractionation is detailed in section 2.5.2.  
Gels used consisted of a resolving gel and a stacking gel (see section 2.2). 
To 12mL of resolving gel, 30μL APS (10% (w/v) Ammonium Persulphate) and 30μL 
TEMED from Flow-gen Bioscience (Nottingham, UK) were added before being 
poured between glass plates. Water was poured above the gel to prevent surface 
dehydration and ensure that it remained level. The resolving gel was allowed to 
polymerise for approximately 25 minutes and water was poured away before 8mL of 
stacking gel, with 30μL APS and 30μL TEMED, was added. This was allowed to 
polymerise, with a gel comb inserted, for approximately 18 minutes. The gels were 
then placed in a BIO-RAD Mini-Protean Tetra system gel tank (BIORAD) which was 
filled with 10X SDS PAGE running buffer. To each well, 10-15μL of cell samples 
were added and resolved against 5μL Spectra BR marker (Thermo). Gels were 
electrophoresed at 100V for 15 minutes and then at 220V for approximately a further 
30 minutes. Proteins were transferred from the gel to an Immobilon-P membrane 
(Mercks) using a BIO-RAD TRANS-BLOT Semi Dry transfer cell. Gels were placed 
on a membrane soaked in methanol, in between two pieces of filter paper (Thermo) 




The membrane was washed in 10mL blocking buffer (see section 2.2), on a 
rocking platform, for 1 hour at room temperature. This buffer was then removed and 
appropriate volumes of primary antibodies (see section 2.1) were added in 10mL 
fresh blocking buffer. The membranes were then incubated with antibodies on a 
rocking platform at 4°C overnight. Antibody buffer was removed and the membrane 
was washed in 10mL PBST on a rocking platform for 5 minutes. This process was 
repeated 3 times. Membranes were then incubated with 10mL blocking buffer 
containing 1/5000 secondary antibody on a rocking platform for 1 hour. Membranes 
were then washed a further 3 times in PBST. Membranes were then soaked in Pierce 
ECL Western Blotting Substrate (Fisher) and exposed to CL-Xposure film (Fisher). 
 
2.5.2 Nuclear and cytoplasmic fractionation  
Ishikawa cell samples were extracted by scraping on ice and harvested at 
1400 RCF for 3 minutes before being re-suspended in 500μL cytoplasmic lysis buffer 
(see section 2.2) and held on ice for 15 minutes. Samples were centrifuged at 13000 
RCF at 4°c for 5 minutes, forming a pellet* and a supernatant. The supernatant was 
transferred to a new tube, centrifuged for a further 10 minutes and the resulting 
supernatant was again transferred to a new tube, producing the cytoplasmic fraction. 
The pellet* was re-suspended in 500μL cytoplasmic lysis buffer, held on ice for a 
further 15 minutes and then centrifuged again at 13000 RCF. The resulting pellet was 
then re-suspended in cell signalling lysis buffer (see section 2.2), with 0.5% (w/v) 
SDS added before use, and held on ice for 10 minutes. This was centrifuged at 
13000 RCF at 4°c for 10 minutes and the resulting supernatant was transferred to a 
new tube, producing the nuclear fraction. Protein concentrations of the fractions were 
equalized based on their absorbance at 595nm which was measured in an Ultrospec 
3000pro spectrophotometer using quick start Bradford 1X dye reagent (BIORAD). 
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2.6 RNA analysis 
 
2.6.1 RNA and cDNA preparation 
Ishikawa cells were extracted by scraping on ice and harvested at 1400 RCF 
for 3 minutes before being re-suspended in 1mL PBS (Sigma). RNA was isolated 
from cells using an RNeasy kit from QIAGEN and cDNA was prepared from this 
using the iScript cDNA synthesis kit from BIORAD. The volume required for 1μg 
cDNA was measured and mixed with 4μL 5X iScript reaction mix, 1μL of reverse 
transcriptase (or molecular biology water for NRT controls) and enough water to 
make the mixtures up to 20μL. This was placed in a TC-3000 thermocycler from 
TECHNE, which incubated the mixtures at 25°C for 5 minutes, followed by 42°C for 
30 minutes and then 85°C for a further 5 minutes. 
 
2.6.2 Real Time PCR 
Real time PCR was performed using a BIORAD Mini Opticon system and 
SYBR Green assay reagents (Fisher). Each well was made up to 20μL with 10μL 
SYBR green (Fisher), 7μL molecular biology water (Panreac AppliChem), 1μL 10μM 
oligonucleotide primers and 2μL cDNA. PCR primers used were from Integrated DNA 
Technologies (Coralville, IO, USA). Primer sequences were as follows: GAPDH 
forward 5′-GAAATCCCATCACCATCTTCCAGG-3′ and reverse 5′-
GAGCCCCAGCCTTCTCCATG-3′; XBP1 forward 5′-GCGCCTCACGCACCTG-3′ and 
reverse 5′-GCTGCTACTCTGTTTTTCAGTTTCC-3′; Rab31 forward 5′-
CGAGCACATGATGGCGATACG-3′ and reverse  
5′-GTCCTTCAGCAGTGCACAGGA-3′; PGR forward 5′-CGCGCTCTACCCTGCACT-
3′ and reverse 5′-TGAATCCGGCCTCAGGTAGTT-3′; TFF1 forward 5’-
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CATCGACGTCCCTCCAGAAGAG-3’ and reverse 5’-
CTCTGGGACTAATCACCGTGCTG-3’; Greb1 forward 5’-
CAAAGAATAACCTGTTGGCCCTGC-3’ and reverse 5’- 
GACATGCCTGCGCTCTCATACTTA-3’; VDR forward 5’-






















2.7 Colony formation assays 
 
2.7.1 Cell seeding and growth 
Stable Ishikawa cell lines (V-Ishikawa, B-Ishikawa, shNeg Ishikawa, 
shBASP1 Ishikawa), detailed in section 2.4, were seeded in 2mL DMEM growth 
media (with G418 as in section 2.3.1) at 500 cells per well. Cells were counted before 
seeding using an Invitrogen Countess automated cell counter. After incubating (as in 
section 2.3.1) for 24 hours, the cells were treated with 100nM tamoxifen (Sigma) or 
vehicle control ethanol (Sigma). Cells were incubated with 100nM tamoxifen media 
for 72 hours before media was changed to fresh DMEM growth media (without 
tamoxifen). Cells were grown for a further 9 days before fixation.  
 
2.7.2 Cell fixing 
The media was removed and plates were washed with 2mL PBS (Sigma) 
before being fixed with 1mL methanol for 10 minutes. Methanol (Sigma) was then 
aspirated and the plates were stained in 0.5% (w/v) crystal violet (Sigma) with 25% 
(v/v) methanol (Sigma) for a further 10 minutes. Crystal violet was then removed and 
plates were washed with distilled water before being photographed. Colonies visible 








2.8 Growth assays 
Ishikawa stable cell lines (V-Ishikawa, B-Ishikawa, shNeg Ishikawa, shBASP1 
Ishikawa), detailed in section 2.4, were seeded onto 6cm plates at 2X105 cells per 
plate. Cells were seeded in 4mL DMEM media (with G418 as in section 2.3.1) per 
plate. Cells were incubated for 24 hours before being treated with 100nM tamoxifen 
(sigma) or vehicle control ethanol (sigma) for the remainder of the assay. Total plate 
cell number was counted, using an Invitrogen countess automated cell counter, every 



















2.9 ChIP analysis  
 
2.9.1 Cell sample fixing 
ChIP assays were performed on Ishikawa cells. 5µL protein magG 
dynabeads (Invitrogen) were mixed with 0.6mL low salt IP buffer (see section 2.2) 
and 1mL 10mg/mL Bovine Serum Albumin (BSA) Sigma in three tubes. Anti IgG, 
BASP1 and ERα antibodies were added to the separate tubes. Antibody-bead 
mixtures were rotated at 4˚c for a minimum of 4 hours *. 1X107 Ishikawa cells were 
extracted per ChIP experiment and centrifuged. Cells were re-suspended in PBS 
(Fisher) to make a concentration of 1X106cells.mL-1. 40µL 37% (v/v) PFA (Sigma) 
was added per mL of sample and the resulting mixture was then incubated on a 
rocker at room temperature for 15 minutes. 141µL.mL-1 of 1M ice cold glycine 
(Promega) was added and incubated as before for a further 5 minutes. Cells were 
harvested, supernatant was removed and pellet was re-suspended in PBS.  
 
2.9.2 Sonication  
The resulting sample (see 2.10.1) was harvested again, the supernatant was 
removed and the pellet was re-suspended in 1mL low salt ChIP buffer (see section 
2.2) with 1X protease inhibitor (Calbiochem). This was held on ice for 15 minutes 
before being centrifuged at 4000RCF at 4°c for 5 minutes. The resulting pellets were 
then re-suspended in 1mL low salt ChIP buffer (see section 2.2) with 1X protease 
inhibitor (Calbiochem) and subjected to sonication. Sonication was performed using a 
QSONICA sonicator. Sonication settings were varied (see section 4.11) but in all 
cases the probe was inserted just over halfway into the sample and was not allowed 
to touch the edges of the tube **. 
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2.9.3 Agarose gel electrophoresis  
For sonication optimisation, DNA fragment size was measured using agarose 
gel electrophoresis. After sonication ** (see 2.10.2) 20μL samples of the sonicated 
mixtures were added to 30μL of PK buffer (see section 2.2) and 1μL RNase A 
(Invitrogen). Samples were incubated at 37°c for 30 minutes. To each of the samples, 
1μL proteinase K (Ambion) was added, and these were then incubated at 62°c for 2 
hours. Following de-crosslinking 5μL of each sample was added to 1μL 6X DNA 
loading dye (Thermo) and resolved on an agarose gel alongside gene ruler low range 
DNA ladder (Thermo). The agarose gel was made up with 1% agarose (Fisher). Gels 
were run in 1X Tris-Acetate-EDTA (TAE) buffer (Fisher) at 120V for approximately 40 
minutes in a BIO-RAD Mini-sub Cell GT. After electrophoresis, gels were placed in 
1X TAE buffer (Fisher) with 1/10000 ethidium bromide (VWR Prolabo). Gels were 
then visualised using a GelDoc-It TS Imaging System.  
 
2.9.4 ChIP protocol 
After sonication ** (see 2.10.2) samples were centrifuged at 12000RCF for 10 
minutes at 4°c and the resulting supernatant was transferred to new tubes. These 
were each mixed with 10μL protein magG dynabeads (Invitrogen), and then rotated 
at 4°C for 1 hour. Sample-bead mixtures were magnetised for 1 minute to harvest the 
beads and 200μL of the remaining sample was added to each of the bead-antibody 
mixtures * (see 2.10.1). To an empty tube, 4μL of the remaining sample was added, 
to be used as a pre-clear, and stored at -20°C. The sample-bead-antibody mixtures 
were rotated overnight at 4°c.  
Sample-bead-antibody mixtures were magnetised for at least 1 minute, the 
remaining liquid was removed, and the beads were re-suspended in 1mL ice cold low 
Salt IP buffer (see section 2.2) without inhibitors. The resulting mixture was held on 
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ice for 3 minutes. This was repeated with high salt ChIP buffer (see section 2.2), 
followed by LiCl buffer (see section 2.2), and then by TE buffer (see section 2.2). TE 
buffer samples were magnetized for at least one minute and the remaining liquid was 
removed. Each of the resulting bead samples and the pre-clear from -20°c storage 
were separately re-suspended in 100μL PK buffer (see section 2.2) and incubated at 
65°C overnight.  
 
2.9.5 DNA purification and PCR 
Beads were re-suspended by vortexing and 1µL 20mg/mL Proteinase K 
(Ambion) was added before incubating at 55˚c for 3-4 hours. Following incubation, 
the samples were centrifuged at 13000 RCF for 5 minutes and supernatants were 
transferred to new tubes. DNA was extracted using a QIA-Quick PCR purification kit 
(QIAGEN) and DNA samples were incubated at 95˚C for 10 minutes. The resulting 
DNA samples were then used to perform qPCR analysis (as described in section 
2.7.2) to quantify the extent of protein binding to target genes relative to BAX21nt. 
The following ChIP primers were used: PGR forward 5′-
AATGAGGCTGACATTCTGGGA-3′ and reverse 5′-GTTGACCTCATTCCAAGGCAG-
3′; Greb1 forward 5’-TCTGAAGGGCAGAGCTGATAA-3’ and reverse 5’-
GAATGACCCAGTTGCCACAC-3’; BAX21nt forward 5’-





























As described earlier (see section 1.3.4) a previous publication from our 
laboratory established that, in MCF7 breast cancer cells, BASP1 interacts with and 
colocalises with ERα in the nucleus. In addition, it was revealed that BASP1 was 
required for approximately 40% of gene expression changes induced by Tamoxifen 
treatment in these cells (44). This indicated that BASP1 could be a novel ER 
modulator capable of affecting cancer cell response to tamoxifen. It is therefore 
possible that BASP1 activity or function is different in endometrial cancer cells from 
breast cancer cells and that this could potentially contribute to the difference in 
tamoxifen response between the cell types. In order to test this possibility, the 
response of ER+ endometrial cells to differing levels of BASP1 expression and 
tamoxifen treatment was investigated. This study used Ishikawa cells (see section 
2.3.1), an ER+ endometrial adenocarcinoma cell line, to produce stable cell lines that 
either over or under express BASP1. In order to investigate BASP1 function in these 
cells, it was first necessary to confirm the expression of BASP1, ERα and WT1. WT1 
was included because BASP1 is known to act as a transcriptional co-suppressor for 
WT1 in other cell types (see section 1.2.3) (17). 
In addition to the interaction between BASP1 and ERα that has recently been 
observed in MCF7 cells (Marsh), BASP1 has been found to exhibit tumour 
suppressor activity in multiple other cancer cell types (40-42) and also to exhibit 
tumour promoting activity in cervical cancer cells (43). It is currently not known by 
which mechanisms BASP1 exerts this activity. It is possible that the BASP1-ERα 
interaction also occurs in other cancer cell types than breast cancer cells, but it is 
also possible that BASP1 exerts these effects by interaction with WT1 or by novel, 
presently unknown mechanisms of action. For this reason, it was of interest to 
observe the changes in phenotype induced by changes in BASP1 expression as well 
as the changes in gene expression. 
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The experiments presented in this chapter were conducted to confirm the 
expression of BASP1, ERα and WT1 in Ishikawa cells and investigate the subcellular 
localisation of BASP1 and ERα. In addition, qPCR analysis of the Ishikawa cell 
response to E2 and tamoxifen treatment was conducted to confirm that tamoxifen 
acts as an ER agonist in these cells, in accordance with the literature on the subject 
(95). Finally, growth assays and colony formation assays of Ishikawa stable cell lines 
were conducted in order to determine the effects of BASP1 expression on Ishikawa 

















3.2 Ishikawa cell expression of BASP1, WT1 and ERα 
Ishikawa whole cell extracts were subjected to immunoblotting to determine 
the expression levels of BASP1, ERα and WT1 in the cells. Whole cell extracts were 
prepared from several cell lines as follows. MCF7 cells that contain a negative control 
shRNA (sh-Neg MCF7), MCF7 cells that contain an shRNA that targets BASP1 (sh-
BASP1 MCF7), Ishikawa cells, K562 cells that contain a control pcDNA3 vector (V-
K562) and K562 cells that contain a pcDNA3 vector driving expression of BASP1 (B-
K562) were subjected to immunoblotting. Samples were probed for β-actin, BASP1, 
ERα and WT1. β-actin served as a control to demonstrate the similar overall protein 
concentrations between samples. V-K562 cells served as a negative control as they 
do not express BASP1. B-K562 cells served as a positive control as they highly 
express C-terminal HA tagged BASP1. The results confirmed that Ishikawa cells 






Figure 7 - Immunoblotting of Ishikawa cells for BASP1, ERα and WT1. 
BASP1, ERα and WT1 are all expressed by Ishikawa cells. Whole cell extracts of shNeg 
MCF7, shBASP1 MCF7, Ishikawa, V-K562 and B-K562 cell lines were used to perform 
western blots. Cell samples were immunoblotted with antibodies for β-actin, BASP1, ERα and 
WT1. β-actin served as a control to ensure similar overall protein concentration between 
samples. Molecular weight markers are shown to the left of the blots (kDa). The blots shown 
are representative of 3 independent experiments. B-K562 cells contain a pcDNA3 vector that 
expresses BASP1 with HA and FLAG tags which cause the protein to run slower on the gel. 
BASP1 expressed in MCF7 and Ishikawa cells is endogenous BASP1. Three isoforms of ERα 
are expressed in MCF7 and Ishikawa cells, including ERα-36 and ERα-66. Both +17AA and -
17AA WT1 isoform bands are clearly visible in MCF7s and Ishikawa cells.    
 
Figure 7 shows that Ishikawa cells express BASP1, ERα and WT1. While 
BASP1 expression appears lower in the Ishikawa cells than in MCF7 cells, the β-
actin concentration is clearly higher in the MCF7 cell line samples so this comparison 
cannot be drawn. In addition to the similar expression of BASP1 between the cell 
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types, BASP1 also has similar mobility in both Ishikawa cells and MCF7 cells. As 
expected, BASP1 in the B-K562 cell lane has reduced mobility compared with the 
endogenous BASP1 expressed in the other cell types. This reduced mobility is due to 
the presence of C-terminal HA and FLAG tags in BASP1 that is expressed from 
pcDNA3 vectors. WT1 expression is also similar in both MCF7 cells and Ishikawa 
cells. Both the 17AA+ and 17AA- isoforms of WT1 are clearly visible in Ishikawa cells 
and MCF7s. This can be compared to the K562 cell lines which predominantly 
express the 17AA+ isoform, as indicated by the strong lower motility WT1 bands in 
these wells. ERα expression and motility was also similar between MCF7 cells and 
Ishikawa cells. The presence of slower migrating ERα-66 and faster migrating ERα-
36 bands are clearly visible in both cell types, in addition to a third ERα isoform with 
intermediate mobility. This could be one of two more known isoforms, ERα-47 or 
ERα-53. ERα expression was also detected in K562 cells, and this result was 
reproducible. This was not anticipated and has not been reported before. However, 
the presence of the additional third ERα isoform found in Ishikawa cells and MCF7 
cells was not detected in K562 cells. Taken together, these results confirm that 
Ishikawa cells express BASP1, ERα and WT1 and indicate that the expression and 












3.3 Subcellular localisation of BASP1 and ERα 
It was previously shown in our laboratory that BASP1 was located in both the 
nucleus and the cytoplasm of MCF7 cells and K562 cells (16, 44). Nuclear and 
cytoplasmic fractionation was performed to determine the intracellular localisation of 
BASP1 and ERα in Ishikawa cells. Overall protein concentrations of subcellular 
fractions were equalized based on absorbance at 595nm, measured by Bradford 
assays. The fractions were then immunoblotted using antibodies for LAMIN A/C, β-
tubulin, BASP1 and ERα. Lamin A and Lamin C are proteins found exclusively in the 
nucleus and served as a control to monitor any nuclear contamination of the 
cytoplasmic fraction. β-tubulin is found exclusively in the cytoplasm and served as a 
control to evaluate cytoplasmic contamination of the nuclear fraction. 
 
Figure 8 - Subcellular fractionation and immunoblotting, for BASP1 and ERα, of 
Ishikawa cells +/- E2. 
Ishikawa cells were incubated for 24 hours with either 100nM E2 or the equivalent volume of 
the vehicle control, H2O. Treatment is indicated above the figure by either E2- (H2O treated) 
or E2+ (E2 treated). Cells were collected, nuclear and cytoplasmic fractionation was 
conducted and overall protein concentrations of the fractions were equalized based on 
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absorbance at 595nm, measured by Bradford assay. Fractions were subjected to 
immunoblotting with antibodies for Lamin A/C, β-tubulin, BASP1 and ERα. Lamin A/C served 
as a nuclear protein control and β-tubulin served as a cytoplasmic protein control. Molecular 
weight markers are shown to the left of the blots (kDa). Blots shown are representative of 3 
independent experiments. 
 
In non-E2 treated Ishikawa cells (fig.8a), no nuclear contamination of the 
cytoplasmic fraction by Lamin A/C was detected (panel 1), while very slight 
cytoplasmic contamination of the nuclear fraction by β-tubulin was evident (panel 2). 
This could be caused by a small amount of cytoplasmic protein remaining adhered to 
the nuclei or by experimental error during fractionation. BASP1 was only detected in 
the cytoplasmic fraction (panel 3) indicating either that it is not located in the nucleus 
or that it is present in levels too low to be detected by immunoblotting. ERα was 
primarily detected in the cytoplasmic fraction (panel 4). There was some very slight 
detection of ERα in the nucleus; however this may have been due to cytoplasmic 
contamination of the nuclear fraction.   
In E2 treated Ishikawa cells (fig.8b), no nuclear contamination of the 
cytoplasmic fraction by Lamin A/C was detected (panel 1) and very low cytoplasmic 
contamination of the nuclear fraction by β-tubulin was detected (panel 2). ERα was 
detected in both the cytoplasmic and nuclear fractions (panel 4), indicating that E2 
treatment resulted in the nuclear localisation of the ER. This is supported by 
numerous publications that have demonstrated this effect in a host of different cell 
types (96). BASP1 was detected primarily in the cytoplasmic fraction (panel 3). An 
extremely faint band is just visible in the nuclear fraction but this could be due to very 
slight cytoplasmic contamination of the nuclear fraction (as evidenced in the -tubulin 
blot). 
These results confirm that, in Ishikawa cells, E2 treatment results in nuclear 
localisation of ERα. The results also indicate that, in Ishikawa cells, BASP1 is 
primarily a cytoplasmic protein. However, it is possible that BASP1 is present in the 
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nucleus at levels too low to be observed by immunoblotting. This is in contrast to 
what was previously observed in MCF7 and several other cell lines in our laboratory, 
in which BASP1 was detected in the nuclear extract (16, 44). The 
nuclear/cytoplasmic distribution of BASP1 was not altered by treatment of Ishikawa 






















3.4 Effect of E2 and Tamoxifen treatment on ER target gene expression in 
Ishikawa cells 
As stated previously, endometrial cells have been shown to respond 
differently to Tamoxifen treatment than breast cancer cells (78, 79). Tamoxifen 
generally stimulates ER target genes in endometrial cancer cells (97). The 
experiments in the following figure were conducted to confirm this ER agonist activity 
in the Ishikawa cells before going on to analyse the effects of BASP1 on tamoxifen 
action. Ishikawa cells were incubated with either 100nM E2, E2 vehicle control (H2O), 
100nM tamoxifen or tamoxifen vehicle control (ethanol) for 24 hours before the cells 
were collected and RNA was prepared. The RNA served to prepare cDNA which was 
then subjected to qPCR using primers for Greb1, PGR and TFF1. Greb1 and TFF1 
genes are both regulated by ERα and both contain EREs, indicating the classical 
pathway of ER activity (98, 99) (see section 1.4.4). PGR is regulated by ERα but 
does not contain any EREs near transcriptional start sites, indicating other 
mechanisms of ERα activity (100). Greb1, PGR and TFF1 were selected because 
they are all well-established ERα target genes shown to be upregulated by E2 





Figure 9 - qPCR to analyse the expression of ERα target genes Greb1, PGR and TFF1 in 
Ishikawa cells +/-E2 and +/-TAM. 
a) Ishikawa cells were incubated for 24 hours with either 100nM E2 or the equivalent volume 
of the vehicle control H2O. Treatment is indicated to the right of the figure by either E2- (H2O 
treated) or E2+ (E2 treated). RNA and cDNA were prepared. GREB1, PGR and TFF1 
expression levels, relative to the control GAPDH, were quantified by qPCR. Error bars are 
standard deviation from the means for each gene (n=3). Unpaired two tailed t-tests were 
performed on the data to determine the significance of difference in expression of each gene 
between treated and untreated cells. P values are indicated above each bar in the graph.  b) 
Same protocol as part a, but Ishikawa cells were incubated with 100nM tamoxifen or the 
vehicle control (ethanol) rather than E2 and H2O. Treatment is indicated to the right of the 
figure by either TAM- (ethanol treated) or TAM+ (tamoxifen treated).  
 
The results indicated that E2 treatment of Ishikawa cells resulted in increased 
expression of Greb1 and PGR (fig.9a). Unpaired two tailed t-tests were performed on 
the data. The increase in expression of PGR was extremely statistically significant 









(P=0.079). However, only three repeats were conducted and one repeat showed very 
little Greb1 increase. If further repeats are conducted, it is possible that the increase 
in Greb1 expression will then be considered significant. Interestingly, TFF1 was 
unaffected by E2 treatment (fig.9a) (P=0.769). This is contrary to what was seen in 
MCF7 cells which suggests that there is some difference in estrogen receptor activity 
between the two cell types. The results also indicated that tamoxifen had a similar 
effect to that observed with E2 on the expression of these genes in Ishikawa cells. 
The increase in expression of PGR was significant (P=0.0178) while the increase in 
Greb1 expression was not (P=0.2510). Again, there was no significant change in 
TFF1 expression. The similar effects of E2 and tamoxifen on the expression of these 




















3.5 Effect of BASP1 expression on Ishikawa cell proliferation 
With the estrogenic activity of Tamoxifen in Ishikawa cells confirmed, 
experiments were conducted to examine the effects of changing BASP1 expression 
on tamoxifen action in the cell type. Ishikawa cell phenotype was investigated by 
conducting growth assays and colony formation assays using stable Ishikawa cell 
line derivatives that express different levels of BASP1 (see section 2.4).  
To produce pcDNA3 stable cell lines, Ishikawa cells were transfected with either an 
empty pcDNA3 vector (V-Ishikawa) or a pcDNA3 vector that contains a BASP1 
expressing region (B-Ishikawa). This produces a stable cell line that expresses HA-
FLAG tagged BASP1 in addition to endogenous BASP1. To produce pSilencer stable 
cell lines, Ishikawa cells were transfected with either a control pSilencer vector (sh-
NEG Ishikawa), resulting in expression of a negative control shRNA, or a pSilencer 
BASP1 vector (sh-BASP1 Ishikawa), resulting in expression of an shRNA that targets 
BASP1. Both pcDNA3 and pSilencer vectors contain a neomycin resistance region. 
Successfully transfected cells can then be selected using G418, a neomycin sulfate 
analogue. First, to identify the optimum concentration of G418, a G418 titration was 
conducted. Ishikawa cells were seeded onto a 6 well plate and treated with a range 
of G418 concentrations from 80-240μg.mL-1. Optimum G418 concentration was 
found to be 200μg.mL-1 which resulted in total Ishikawa cell death after 8 days. All 
four Ishikawa stable cell lines produced were pools of cells. 
V-Ishikawa and B-Ishikawa stable cell line whole cell extracts were subjected 
to immunoblotting using antibodies for β-actin and BASP1.  β-actin served as a 
control to demonstrate the similar overall protein concentrations between samples. V-
K562 cells served as a negative control as they do not express BASP1. B-K562 cells 
served as a positive control as they highly express C-terminal HA tagged BASP1. 
Results confirmed that the B-Ishikawa stable cell line overexpresses BASP1 
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compared to the V-Ishikawa cell line. Similar to the B-K562 cells, the ectopically 
expressed epitope-tagged BASP1 exhibits slower migration in the gel compared to 
the endogenous BASP1 in the Ishikawa cells. For growth assays, V-Ishikawa cell 
proliferation rate was compared to that of B-Ishikawa cells. Cells were seeded at 
150,000 cells per plate and grown for 96 hours, with cell counts every 24 hours. After 
the first 24 hours, cells were treated with either 100nM tamoxifen or the equivalent 





Figure 10 - Growth assays of V-Ishikawa and B-Ishikawa cell lines +/- TAM 
a) Whole cell extracts of V-Ishikawa and B-Ishikawa stable cell lines, with V-K562 and B-K562 
cells, were used to perform western blots. Cell samples were immunoblotted with antibodies 
for β-actin and BASP1. β-actin served as a control to ensure similar overall protein 
concentration between samples. Molecular weight markers are shown to the left of the blots 
(kDa). Blots shown are representative of 3 independent experiments. b) V-Ishikawa and B-
Ishikawa cell lines were seeded at 1.5X10
5
 cells per plate. After 24 hours, cells were treated 
with 100nM TAM or the equivalent volume of the vehicle control ethanol. Cells were grown for 
a total of 96 hours with cell counts being taken every 24 hours. Error bars are standard 
deviation   from the mean at each time point (n=3). Repeated measures two-way ANOVA with 





The results indicated that increased BASP1 expression reduces proliferation 
rate in Ishikawa cells. Two-way ANOVA testing revealed that B-Ishikawa cell count 
was significantly less than that of the V-Ishikawa cell line after 24 hours (0.000652) 
and at every subsequent time point. Whilst TAM treated cells appear to grow 
marginally faster than untreated cells, this difference was shown to be not significant 
at the majority of time points. At the 48 hour and 72 hour time points, TAM treatment 
resulted in no significant change in cell number. However, Tamoxifen treated B-
Ishikawa cells were found to have proliferated significantly more than untreated V-
Ishikawa cells, at the 96 hour time point only (P=0.004659). Tamoxifen treated B-
Ishikawa cell number was not quite significantly different from that of untreated V-
Ishikawa cells (P=0.061057). 
To determine whether decreasing BASP1 expression had the opposite effect, 
growth assays were conducted using the sh-Neg and sh-BASP1 Ishikawa cell lines. 
Immunoblotting and growth assay protocols were the same as in figure 10, but sh-
Neg and sh-BASP1 Ishikawa cells were used instead of V-Ishikawa and B-Ishikawa 
cells. Also, K562 cells were not included in the immunoblotting as there was no need 
to show the different migratory speeds of endogenous and HA-FLAG tagged BASP1. 
Immunoblotting results confirmed that the sh-BASP1 Ishikawa stable cell line under-





Figure 11 - Growth assays of sh-Neg and sh-BASP1 Ishikawa cell lines +/- TAM 
a) Whole cell extracts of sh-Neg and sh-BASP1 Ishikawa stable cell lines were used to 
perform western blots. Cell samples were immunoblotted with antibodies for β-actin and 
BASP1. β-actin served as a control to ensure similar overall protein concentration between 
samples. Molecular weight markers are shown to the left of the blots (kDa). Blots shown are 
representative of 3 independent experiments. b) sh-Neg and sh-BASP1 Ishikawa cell lines 
were seeded at 1.5X10
5
 cells per plate. After 24 hours, cells were treated with 100nM TAM or 
the equivalent volume of the vehicle control ethanol. Cells were grown for a total of 96 hours 
with cell counts being taken every 24 hours. Error bars are standard deviation from the mean 
at each time point (n=4). Repeated measures two-way ANOVA with a Bonferroni’s post hoc 
analysis and a student’s t-test were performed for each time point.  
 
The results of the growth assays indicated that reducing BASP1 expression 
increases the proliferation rate in Ishikawa cells. Two-way ANOVA testing revealed 
that sh-BASP1 Ishikawa cell count was significantly greater than that of the sh-Neg 
Ishikawa cell line after 48 hours (P=0.005291) and at every subsequent time point. 
Tamoxifen treatment produced no significant change in cell count at any time point. 
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3.6 Effect of BASP1 expression on Ishikawa cell colony formation efficiency 
Growth assays of Ishikawa cells indicated that increased BASP1 expression 
results in reduced proliferation and that decreased BASP1 expression results in 
increased proliferation. Colony formation assays were performed to further 
investigate the effects of BASP1 expression on Ishikawa cell proliferation and 
survival. Colony formation efficiency of B-Ishikawa cells was compared to that of V-
Ishikawa cells.  
For colony formation assays, cells were seeded onto 6-well plates at 500 cells 
per well and grown for 13 days before fixing with methanol. After the first 24 hours 
cells were treated with either 100nM tamoxifen / vehicle control (ethanol) or 100nM 
estradiol / vehicle control (water) for 72 hours. Colonies with a cell number greater 






Figure 12 - Colony formation assays of V-Ishikawa and B-Ishikawa cells +/- TAM and E2 
V-Ishikawa and B-Ishikawa stable cell lines were seeded onto 6 well plates at 500 cells per 
well. After 24 hours, cells were incubated with either 100nM E2, E2 vehicle control H2O, 
100nM TAM or TAM vehicle control ethanol for 72 hours. Cells were grown for a further 11 
days before colonies were fixed in methanol and stained using crystal violet. Total numbers of 
colonies visible with the naked eye were counted and used to calculate colony forming 
efficiencies (n=3). Repeated measures two-way ANOVA with a Bonferroni’s post hoc analysis 
and a student’s t-test were performed for each time point. T-test P values are indicated above 
each bar in the graph. 
 
Repeated measures two-way ANOVA testing indicated that there was a 
significant difference in colony formation efficiency between V-Ishikawa and B-
Ishikawa cell lines, but that there was no significant difference between drug and 
vehicle control treatments. Unpaired two tailed t-test confirmed that colony formation 
efficiency was significantly lower in the B-Ishikawa cells compared to the V-Ishikawa 
73 
 
cells in all cases. In addition, colonies formed by the B-Ishikawa cells appear to be 
smaller on average than those of the V-Ishikawa cells. 
To further investigate the effect of altered BASP1 expression on colony 
formation efficiency, colony formation assays were conducted using the sh-Neg and 
sh-BASP1 Ishikawa cell lines. Assay protocols were the same as in figure 12, but sh-
Neg and sh-BASP1 Ishikawa cells were used instead of V-Ishikawa and B-Ishikawa 
cells.  
 
Figure 13 - Colony formation assays of sh-Neg and sh-BASP1 Ishikawa cells +/- TAM 
and E2 
sh-Neg and sh-BASP1 Ishikawa stable cell lines were seeded onto 6 well plates at 500 cells 
per well. After 24 hours, cells were incubated with either 100nM E2, E2 vehicle control H2O, 
100nM TAM or TAM vehicle control ethanol for 72 hours. Cells were grown for a further 9 
days before colonies were fixed in methanol and stained using crystal violet. Total numbers of 
colonies visible with the naked eye were counted and used to calculate colony forming 
efficiencies (n=3). Repeated measures two-way ANOVA with a Bonferroni’s post hoc analysis 
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and a student’s t-test were performed for each time point. T-test P values are indicated above 
each bar in the graph. 
 
As was seen in the pcDNA3 Ishikawa cell lines, repeated measures two-way 
ANOVA testing indicated that there was a significant difference in colony formation 
efficiency between sh-Neg and sh-BASP1 Ishikawa cell lines. This was confirmed by 
unpaired two tailed t-tests which indicated that the colony formation efficiency of sh-
BASP Ishikawa cells was significantly greater than that of sh-Neg Ishikawa cells in all 
conditions apart from the E2 treated cells. The E2 treated sh-BASP1 Ishikawa cells 
colony formation efficiency was slightly more variable than the untreated and TAM-
treated cells. Since the colony formation efficiency of E2 treated sh-BASP1 Ishikawa 
cells was higher than the colony formation efficiency of E2 treated sh-Neg Ishikawa 
cells in all repeats, and the increase was taken to be only slightly non-significant, it is 
probable that another repeat at these conditions would produce a significant result. 
Additionally, colonies formed by the sh-BASP1 Ishikawa cells appear to be larger on 
















The results in this section have confirmed the expression of BASP1, ERα and 
WT1 in Ishikawa cells (fig.7), and have confirmed the ERα agonist activity of 
tamoxifen (fig.9). However, subcellular fractionation and immunoblotting failed to 
detect the presence of BASP1 in the nucleus of Ishikawa cells (fig.8). It has 
previously been shown that, in MCF7 cells, BASP1 is present in the nucleus at levels 
detectable by immunoblotting and that BASP1 can be found at the promoters of ER 
target genes. Since it has been shown that the tamoxifen response in MCF7s is 
affected by BASP1 expression, it is possible that this difference in nuclear 
localisation of BASP1 between the MCF7 cells and Ishikawa cells could result in 
differences in tamoxifen response. 
It should be noted that it is possible that BASP1 is present in the nucleus at 
levels too low to be detected by immunoblotting but it is also possible that it is an 
entirely cytoplasmic protein, under these conditions, in this cell type. BASP1 has 
previously been shown to regulate gene expression in other cell types, despite being 
primarily cytoplasmic in these cells. In iPSCs, inhibition of BASP1 has been shown to 
result in increased WT1 activation (101) despite not being detected in the nucleus by 
immunofluorescence. It is possible that low levels of BASP1 in the nucleus are 
sufficient to mediate transcriptional regulation. Alternatively, BASP1 could influence 
transcription from the cytoplasm by interacting with other transcription factors. In 
Ishikawa cells ERα can be found in both the nucleus and the cytoplasm (fig.8).  WT1 
has also been shown to be present in both the nucleus and cytoplasm in other cell 
types (102). It is therefore possible that BASP1 might retain either WT1 or ERα in the 
cytoplasm, or otherwise influence their nuclear import, resulting in changes in gene 
expression. In future, immunofluorescence could be conducted to analyse the 
nuclear and cytoplasmic distribution of BASP1 in order to confirm the subcellular 
fractionation results.  
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Quantitative PCR to measure the mRNA of ERα target genes in Ishikawa 
cells following E2 or tamoxifen treatment revealed multiple differences in tamoxifen 
treatment response between the two cell types. Tamoxifen exhibited estrogenic 
activity in Ishikawa cells which is in contrast to its effects in MCF7 cells which are 
anti-estrogenic. These results are supported by numerous other studies on the 
subject (78, 79, 97). It was expected that tamoxifen would exhibit estrogenic activity 
on key ER target genes and this was confirmed in the case of PGR expression. 
However, TFF1 expression was unchanged in response to either E2 or tamoxifen 
treatment (fig.9). This data suggests that there may be differences in ERα target 
genes and mechanisms of activity between the cell types, in addition to the difference 
in ER agonist/antagonist response to tamoxifen. These results are consistent with 
previous RNA sequencing data of Ishikawa cells which showed that PGR and Greb1 
were significantly upregulated by E2 and Tamoxifen treatment but TFF1 was not 
(103). 
Colony formation assays showed that increased BASP1 expression resulted 
in a decrease in CFE (%) and decreased BASP1 expression resulted in an increase 
in CFE (%) in all repeats. ANOVA testing indicated significant difference in colony 
formation efficiency between the B-Ishikawa and V-Ishikawa and between the sh-
BASP1 Ishikawa and sh-Neg Ishikawa cell lines. Student’s t-tests indicated that 
these changes could be accepted as significant in all conditions apart from the E2 
treated pSilencer Ishikawa cells. In this case, the slightly non-significant result was 
partially due to the higher level of variation in colony formation efficiency in the E2 
treated sh-BASP1 cells. A possible reason for the high level of variation in CFE (%) is 
that the Ishikawa cells used grow well at high cell densities but exhibit highly variable 
growth and survival when at very low cell numbers. This hypothesis is supported by 
the results of growth assays showing that BASP1 expression reduces proliferation in 
Ishikawa cells. In the growth assays, B-Ishikawa cells showed reduced proliferation 
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compared with V-Ishikawa cells in all cases and sh-BASP1 Ishikawa cells showed 
increased proliferation compared with sh-Neg Ishikawa cells in all cases. For the 
growth assays, cells were seeded in much higher numbers which could have 
reduced the variation caused by Ishikawa cells inconsistent growth and survival rates 
when at very low cell numbers. The results of the growth assays and colony 
formation assays, taken together, indicate that BASP1 possesses tumour suppressor 
activity in Ishikawa cells. 
Another observation from the colony formation assay was that BASP1 
expression appeared to reduce the average colony size. These colony formation 
assays and growth assays, taken together, indicate that BASP1 exhibits tumour 
suppressor activity in Ishikawa cells. This activity would suggest that BASP1 is 
capable of regulating transcription.  It is not known by what mechanism BASP1 elicits 
these effects, but it is possible that this could be being carried out by very low, 
undetected levels of BASP1 in the nucleus, or by interactions with other transcription 
factors in the cytoplasm such as ERα, WT1 or c-myc.  
The effects of BASP1 on Ishikawa cell growth do not appear to have been 
changed by E2 or TAM treatment in either the growth assays or the colony formation 
assays. However, in the pcDNA3 Ishikawa cell line growth assays, Tamoxifen treated 
B-Ishikawa cells were found to have proliferated significantly more than untreated B-
Ishikawa cells, at the 96 hour time point, while tamoxifen treated V-Ishikawa cell 
number was not quite significantly different from that of untreated V-Ishikawa cells 
(fig.10). This could suggest that BASP1 overexpression may enhance the 
proliferative effect of Tamoxifen on Ishikawa cells, but more repeats with later time 
points would be required to test this.  
BASP1 has previously been shown to enhance the effects of TAM treatment 
in both MCF7 and T47D breast cancer cells (44). While the effects of TAM treatment 
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in breast cancer cells is actually anti-proliferative, it is possible that BASP1 may 
enhance the effects of TAM by the same mechanism across the different cell types. 
Subsequent experiments aimed to investigate whether BASP1 exhibits transcriptional 
modulation activity in Ishikawa cells, despite being primarily cytoplasmic, and 






























4 Analysis of the role of 
















In the previous chapter, immunoblotting failed to detect the presence of 
BASP1 in the nucleus of Ishikawa cells (fig.8) but growth assays and colony 
formation assays indicated that BASP1 may possess tumour suppressive activity in 
the cell type (fig.11). This suggests that BASP1 could modulate gene expression 
through low level BASP1 in the nucleus, or by interacting with other transcription 
factors in the cytoplasm. In other cell types BASP1 has been shown to interact with 
WT1 and ERα and localise at gene promoters (16, 44). 
Growth assays and colony formation assays indicated that BASP1 possesses 
tumour suppressor activity in Ishikawa cells, similarly to that which has been seen in 
MCF7 breast cancer cells (44). However, BASP1 does not appear to alter the effects 
of TAM treatment in Ishikawa cells. The only indication that BASP1 may promote the 
effects of TAM treatment was the 96 hour time point of the pcDNA3 Ishikawa cell 
growth assays. It is possible that this effect would consistently be seen in growth 
assays at later time points, but these experiments will have to be repeated with a 
longer time scale in order to confirm this. These results indicate that BASP1 may be 
capable of modulating gene expression to affect proliferation, but it is not clear 
whether it is capable of modulating Tamoxifen response. This raises the question of 
whether BASP1 mediates any effects through the gene regulatory functions of ER. 
The following experiments were conducted to investigate: the effects of 
BASP1 on gene expression of ERα and WT1 targets, the effects of BASP1 on 
tamoxifen induced gene expression changes, and possible BASP1 binding to ERα 
target gene promoters. Specific transcript levels were analysed using qPCR in an 
attempt to demonstrate possible gene expression modulation by BASP1, as well as 
possible effects of BASP1 on TAM induced gene expression changes. ChIP was 
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performed in an attempt to detect possible low level BASP1 localisation at gene 

























4.2 Effects of BASP1 on gene expression 
In order to investigate possible gene expression modulation by BASP1, qPCR 
for ERα and WT1 target genes was performed on Ishikawa stable cell lines. 
Expression of the chosen genes in B-Ishikawa cells were compared to that of V-
Ishikawa cells. Expression of the chosen genes in sh-BASP1 Ishikawa cells were 
compared to that of sh-Neg Ishikawa cells. RNA was prepared from each of the cell 
lines and cDNA prepared from this before being subjected to qPCR using primers for 
Greb1, PGR, TFF1, Rab31 and VDR. Expression of the ERα target genes (Greb1, 





                  
Figure 14 - qPCR for ERα and WT1 target genes in Ishikawa stable cell lines with 
altered BASP1 expression. 
RNA and cDNA were prepared from V-Ishikawa, B-Ishikawa, sh-Neg Ishikawa and sh-BASP1 
Ishikawa stable cell lines. GREB1, PGR, TFF1, Rab31 and VDR expression levels, relative to 
the control GAPDH, were quantified by qPCR. Error bars are standard deviation from the 
means for each gene (n=6). Unpaired two tailed t-tests were performed on the data to 
determine the significance of difference in expression of each gene, between cell lines with 
differing BASP1 expression. P values are indicated above each bar in the graph. 
 
The results indicated that BASP1 regulates transcription of a subset of ERα 
target genes. Expression of both PGR and TFF1 was significantly reduced in B-
Ishikawa cells compared with V-Ishikawa cells. These suggest that BASP1 may 
repress expression of PGR and TFF1, which are both known ERα targets. However, 
there was no significant difference in PGR expression between the two pSilencer cell 
lines and TFF1 data was not obtained for the pSilencer cell lines. Expression of 





only the expression change of Rab31 was found to be statistically significant. Greb1 
is another ERα target which has been implicated in the proliferative effect of estradiol 
in breast cancer (104). Rab31 is also an ERα target and is a known target of MUC1-
C induced tamoxifen resistance in some breast cancer cases (Kharbanda). VDR is a 
WT1 target (105) and is known to act as a transcription factor which has been 
implicated in several cancer types (106). Greb1, Rab31 and VDR expression was 
reduced in sh-BASP1 Ishikawa cells compared with sh-Neg Ishikawa cells but only 
the expression changes in Greb1 and Rab31 were statistically significant. Taken 
together, these results indicate that BASP1 is able to affect transcription of a subset 

















4.3 Effects of BASP1 on tamoxifen induced gene expression changes in 
pcDNA3 Ishikawa cells 
Growth assays indicated that BASP1 expression reduces the proliferation rate 
of Ishikawa cells and qPCR indicated that BASP1 modulates the expression of a 
subset of ERα target genes. However, it is not known whether BASP1 is able to 
modulate tamoxifen action on the ER in Ishikawa cells, as has been shown 
previously in MCF7 cells (44). The following experiments were conducted in order to 
investigate the effect of BASP1 expression on tamoxifen induced gene expression 
changes. Expression of key ER target genes in the absence or presence of 
tamoxifen was quantified by qPCR. The differences in gene expression between the 
tamoxifen treated and untreated cells in B-Ishikawa cells were compared to that of V-
Ishikawa cells.  
Cells were incubated with either 100nM TAM or equivalent volume of vehicle 
control (ethanol) for 24 hours before the cells were collected and RNA was prepared. 
cDNA was prepared and was then subjected to qPCR using primers for Greb1, PGR, 
TFF1, XBP1, Rab31 and VDR. Expression of the ERα target genes (Greb1, PGR, 










                                                      
Figure 15 - qPCR for ERα and WT1 target genes in V-Ishikawa and B-Ishikawa +/- TAM 
RNA and cDNA were prepared from B-Ishikawa and V-Ishikawa stable cell lines. Cells were 
incubated for 24 hours with either 100nM TAM or the equivalent volume of the vehicle control 
ethanol. Treatment is indicated to the right of the figure by either TAM- (ethanol treated) or 
TAM+ (TAM treated). GREB1, PGR, TFF1, Rab31 and VDR expression levels, relative to the 
control GAPDH, were quantified by qPCR. Error bars are standard deviation from the means 
for each gene (n=6). Unpaired two tailed t-tests were performed on the data to determine the 
significance of difference in expression of each gene.  P values are indicated above each bar 
in the graph.  
 
The results indicated that BASP1 overexpression results in the upregulation 
of a subset of ERα target genes in response to tamoxifen treatment. In B- Ishikawa 
cells, PGR, Greb1 and TFF1 were all upregulated significantly more in response to 
tamoxifen treatment, than in V- Ishikawa cells. There were no significant expression 
changes induced by tamoxifen treatment of XBP1 or Rab31 in either the V-Ishikawa 
cells or B-Ishikawa cells. There was also no significant difference between the two 





P=0.9639 a) b) 
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response to tamoxifen treatment was observed in V-Ishikawa cells but not in B-
Ishikawa cells.  
These results indicate that BASP1 is capable of modifying tamoxifen action in 
Ishikawa cells. Tamoxifen induced expression change was significantly different 
between the two cell types for PGR, Greb1 and TFF1, which are all known ERα 
targets.  In addition, neither TFF1 nor Greb1 showed any significant change in 
expression in response to tamoxifen treatment in V-Ishikawa cells but both showed a 
significant increase in expression in B-Ishikawa cells. This suggests that BASP1 
could be required for tamoxifen to exert its effects on gene expression at a subset of 




















4.4 Effects of BASP1 on tamoxifen induced gene expression changes in 
pSilencer Ishikawa cells 
qPCR of the pcDNA3 Ishikawa stable cell lines indicated that some of the 
expression changes induced by tamoxifen treatment are BASP1 dependent. In order 
to confirm this, the same experiments were conducted on sh-Neg and sh-BASP1 
Ishikawa stable cell lines. Cells were incubated with either 100nM TAM or equivalent 
volume of vehicle control (ethanol) for 24 hours before the cells were collected and 
RNA was prepared. cDNA was prepared from this RNA and was then subjected to 
qPCR using primers for Greb1, PGR, XBP1, Rab31 and VDR. Expression of the ERα 
target genes (Greb1, PGR, XBP1 and Rab31) and the WT1 target gene (VDR) 







                                              
Figure 16 - qPCR for ERα and WT1 target genes in sh-Neg and sh-BASP1 Ishikawa 
cells +/- TAM 
RNA and cDNA were prepared from sh-Neg and sh-BASP1 Ishikawa stable cell lines. Cells 
were incubated for 24 hours with either 100nM TAM or the equivalent volume of the vehicle 
control ethanol. Treatment is indicated to the right of the figure by either TAM- (ethanol 
treated) or TAM+ (TAM treated). GREB1, PGR, Rab31 and VDR expression levels, relative to 
the control GAPDH, were quantified by qPCR. Error bars are standard deviation from the 
means for each gene (n=6). Unpaired two tailed t-tests were performed on the data to 
determine the significance of difference in expression of each gene.  P values are indicated 
above each bar in the graph.  
 
The results indicate that reduced BASP1 expression does not affect 
tamoxifen induced expression changes of these genes. Unlike, in B-Ishikawa cells, 
neither the sh-Neg nor sh-BASP1 stable cell lines showed any significant changes in 
PGR, Greb1 or TFF1 expression induced by tamoxifen treatment. Similar to the 
observations in pcDNA3 Ishikawa cells, in pSilencer Ishikawa cells there were no 
significant expression changes, induced by tamoxifen treatment, of XBP1 or Rab31. 
a) b) P=0.6251 
P=0.3218 


































4.5 Sonication optimisation for ChIP with Ishikawa cells  
The qPCR results indicate that manipulation of the level of BASP1 in Ishikawa 
cells alters the regulation of a subset of ER target genes by tamoxifen (fig.17). It has 
previously been shown in our laboratory that, in MCF7 cells, BASP1 expression is 
required for 40% of Tamoxifen induced expression changes. The proposed 
mechanism for this effect was direct ERα complex binding by BASP1 in the nucleus 
because BASP1 and ERα were shown to co-localise in the nucleus and BASP1 was 
found at the promoters of ERα target genes by ChIP (44). Co-IP experiments in 
Ishikawa cells were not conducted because, if there is any nuclear localisation of 
BASP1, it was likely too low to be detected by immunoblotting (fig.8). However, it is 
possible that very low levels of BASP1 could be detected at the promoters of ERα 
target genes in Ishikawa cells. ChIP experiments were therefore initiated to 
determine if BASP1 can localise to the promoters of ER target genes in Ishikawa 
cells.   
In order to conduct ChIP experiments, it was first necessary to optimise the 
sonication protocol for Ishikawa cells. Ishikawa cells were subjected to varying levels 
of sonication time and power and the resulting fragmented chromatin was resolved 
by agarose gel electrophoresis to determine the size of the resulting DNA fragments. 
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Figure 17 - Sonication optimisation for ChIP of Ishikawa cells 
Chromatin fragments resolved by agarose gel following sonication with varying sonication 
times, repetitions and amplitude. a) Pulses of sonication for 3s, followed by 2s on ice, for 
differing number of rounds (16-32), at 60% amplitude. b) Pulses of sonication for 10s, 
followed by 30s on ice, for differing numbers of rounds (8-24) at 50% amplitude. c) Pulses of 
sonication for 30s, followed by 30s on ice, for 16 rounds, with varying amplitudes (70-90%). 
DNA size markers are shown to the left of the gels, indicated by ‘L’ above the marker well 
(bp). 
 
The Results indicated that increased sonication intensity was required to 
break down the Ishikawa cell chromatin. The results also showed that increasing 
sonication time per pulse had a greater effect on chromatin fragmentation than 
increasing the number of pulses or the amplitude of the sonicator. DNA 
fragmentation improved but a wide spectrum of DNA fragment sizes was produced 
even by the highest intensity sonication. Further optimisation of both the sonication 
and cross-linking protocols is required in order to produce a smaller band of more 




a) b) c) 
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4.6 Investigating localisation of ERα and BASP1 at ERα target gene promoters 
in Ishikawa cells  
Sonication optimisation produced samples of fragmented chromatin that 
included small enough fragments to perform ChIP experiments on. However, the 
DNA fragment sizes produced were highly variable so the cross linking and 
sonication experiments should ideally be further optimised in order to produce 
reliable ChIP data. In an effort to produce preliminary, indicative results, ChIP was 
conducted using the sonication settings set out above.  
Ishikawa cells were incubated with E2 for 24 hours to increase nuclear 
localisation of ERα (fig.8). Cells were collected and DNA was crosslinked with PFA 
followed by fragmentation by sonication. Chromatin was fragmented by pulses of 
sonication for 30s, followed by 30s on ice, for 16 rounds, at 70% amplitude. ChIP 
was performed with control IgG, BASP1 and ERα magG bead-bound antibodies. The 
immuno-precipitated DNA was subjected to qPCR using ChIP promoter primers for 
Greb1 and PGR, and as a negative control the Bax gene. 
 
Figure 18 - ChIP of Ishikawa cells for ERα and BASP1 binding to ERα target genes  
Ishikawa cells were extracted following 24 hour incubation with 100nM E2 and cross linked 
with PFA. Chromatin was extracted and fragmented by sonication. Chromatin fragments were 
probed with antibodies for IgG, BASP1 and ERα antibodies. Binding of BASP1 and ERα to 
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target genes (PGR and Greb1) was quantified relative to the control, BAX1. Fold enrichment 
was calculated relative to IgG. Unpaired two tailed t-tests were performed on the data to test 
significance of difference between ERα/BASP1 and IgG (n=3). P values for each gene are 
indicated above the bars.   
 
ChIP revealed that at both the Greb1 and PGR promoters, BASP1 and ERα 
were both found to have fold enrichments of between 1.59 and 2.10 on average. This 
fold enrichment over the IgG was taken to be not significant due to the high level of 
variation in the magnitude of enrichment. However, BASP1 and ERα samples had a 
fold enrichment of greater than 1 in almost all cases. In addition, it was expected that 
ERα binding would be significant at these promoters but it showed similar fold 


















Gene expression analysis of Ishikawa stable cell lines with manipulated levels 
of BASP1 has indicated that BASP1 is able to modulate gene expression of a subset 
of ERα and WT1 target genes. Since immunoblotting of Ishikawa cell subcellular 
fractions could not detect any BASP1 in the nucleus (fig.9), it is possible that this 
effect is produced by very low levels of BASP1 in the nucleus or by cytoplasmic 
BASP1 activity, such as sequestration of transcription factors. In other cell types, 
BASP1 has been shown to interact with several transcription factors: WT1, ERα and 
c-myc (17, 19, 44).  
Gene expression analysis of tamoxifen treated Ishikawa stable cell lines 
indicated that BASP1 is required for the estrogenic effect of tamoxifen on ERα target 
genes: PGR, TFF1 and Greb1 (Fig.13). In MCF7s, approximately 40% of tamoxifen 
induced gene expression changes were previously shown to be BASP1 dependent. It 
is therefore possible that, despite the opposing effects of tamoxifen treatment on 
gene expression in these cell types, a portion of the activity of tamoxifen is BASP1 
dependent in the same way. Tamoxifen induced expression change of VDR was also 
found to be significantly different in B-Ishikawa cells from that of V-Ishikawa cells. 
VDR is not an ERα target gene but it is possible that this is a secondary effect. 
However, the significant tamoxifen induced reduction in VDR expression seen in N-
Ishikawa cells was not seen in sh-Neg Ishikawa cells. Both V-Ishikawa and sh-Neg 
Ishikawa cell lines are Ishikawa cells that should have normal BASP1 expression 
levels. This would suggest either that this difference between B-Ishikawa cells and V-
Ishikawa cells was an error or that it was not due to differing BASP1 expression. 
Tamoxifen response in Ishikawa cells was altered by increased BASP1 
expression but not by decreased BASP1 expression (fig.15 and fig.16). It is possible 
that the increase in expression of BASP1 in B-Ishikawa cells compared with V-
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Ishikawa cells is greater than the decrease in expression of BASP1 in sh-BASP1 
Ishikawa cells compared with sh-Neg Ishikawa cells. It is also possible that 
endogenous BASP1 expression levels are too low in Ishikawa cells for tamoxifen to 
exert its effects on the expression of these investigated genes. If this is the case, 
then lowering BASP1 levels even further (as in the sh-BASP1 Ishikawa cell line) 
would have no effect on tamoxifen induced expression changes. Since this is what 
was observed (fig.16), it is possible that a certain level of BASP1 expression is 
required for tamoxifen to exert its effects on gene expression. Another possibility is 
that nuclear BASP1 is required for these tamoxifen induced changes. It is possible 
that overexpressed HA-FLAG tagged BASP1 may be localised more in the nucleus 
than endogenous BASP1. If this is the case, then B-Ishikawa cells could have much 
higher levels of BASP1 in the nucleus than the other Ishikawa cell lines, since 
endogenous BASP1 localisation was found to be primarily cytoplasmic (fig.8). This 
could be tested by conducting immunoblotting and immunofluorescence experiments 
on the B-Ishikawa stable cell line. 
ChIP analysis of BASP1 and ERα binding to ERα target genes in Ishikawa 
cells produced non-significant results (fig.18). However, only three repeats were 
conducted, the majority of repeats indicated binding and the cross linking/sonication 
protocols were not fully optimised (fig.17). ERα localisation was measured to provide 
a positive control since ERα is known to localise at the promoters chosen, Greb1 and 
PGR. Since ERα binding was found to be not significant, this would suggest that 
further optimisation of the protocol is needed. This low level, non-significant ChIP for 
ERα is comparable to that of BASP1. This raises the possibility that BASP1 might be 
present at the promoters but further optimisation of the protocol is required in order to 
test this. Protocol optimisation in this project focused on optimisation of the 
sonication procedure. It was found that high power and long pulse times were 
required to improve DNA fragmentation (fig.17). Increasing these further would risk 
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shearing of the DNA fragments due to increased sample temperature caused by the 
sonication. To further optimise the protocol, cross-linking can be optimised by varying 
cross-linker concentration or the incubation time of the cross-linking step. In addition, 
sonication can be further optimised by varying sample volume and sample cell 
concentration.  
Taken together, the results in this chapter indicate that: BASP1 is able to 
modulate gene expression of a subset of ERα target genes, BASP1 is required for 
some tamoxifen induced gene expression changes of ERα target genes, and BASP1 
presence at the promoters of ERα target genes is possible but was not demonstrated 
to be significant. The mechanism of these effects is still unknown but the ChIP data 
raises the possibility that BASP1 might be acting directly at the target genes that it 
































BASP1 as a tumour suppressor 5.1 
Increasing evidence implicates BASP1 in transcriptional control and 
tumourigenicity in a variety of cell and tissue types throughout the human body. 
BASP1 has been shown to exert tumour suppressor activity and to be a target of 
repression in a diverse range of cancer cell types including breast cancer cells, acute 
myelogenous leukaemia cells, hepatocellular carcinoma cells and thyroid cancer 
cells (40-42, 44). Within these cancer cell types, BASP1 has been shown to exert a 
number of different effects including reducing proliferation, migration and colony 
formation, as well as increasing apoptosis. New evidence demonstrates the 
complexity of the functions of BASP1 as it has, by contrast, been found to possess 
tumour promoting activity in cervical cancer cells (43). Again, it was found that 
BASP1 has multiple effects in the cancer type including increasing proliferation, 
colony formation and tumourigenicity, as well as being associated with stage 
progression and poor prognosis.  
The results of this study indicate endometrial cancer as another cancer cell 
type in which BASP1 possesses tumour suppressor activity. Growth assays and 
colony formation assays showed BASP1 expression reduced cell proliferation and 
colony formation in all repeats (fig10-13). These results are similar to those seen in 
acute myelogenous leukaemia cells, hepatocellular carcinoma cells and thyroid 
cancer cells (40-42). This was also a similar effect to that which was shown 
previously in MCF7 and T47D breast cancer cells (44). However, in MCF7 cells the 
magnitude of colony formation efficiency change induced by altering BASP1 
expression was far greater than in Ishikawa cells. It is possible that this was due to a 
greater over-expression of BASP1 in B-MCF7s and greater under-expression of 
BASP1 in shB-MCF7s compared with the B-Ishikawa and sh-BASP1 Ishikawa cell 
lines used in this study. This is supported by immunoblotting of the stable cell lines 
for BASP1, in which it appears that the changes in BASP1 expression were greater 
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in the MCF7 cell lines (fig.10 and 11) (44). However, it is also possible that this 
reduced magnitude of difference in Ishikawa cells compared with MCF7 cells is due 
to the lower nuclear localisation of BASP1.  
In MCF7 cells BASP1 was detectable in the nucleus by immunoblotting, while 
in Ishikawa cells BASP1 was only detected in the cytoplasm (fig.8). The primarily 
cytoplasmic localisation of BASP1 in Ishikawa cells, coupled with BASP1s exhibition 
of tumour suppressor activity, is comparable to that previously observed in some 
other cell types. In iPSCs, BASP1 has been shown to affect transcription despite not 
being detected in the nucleus by immunofluorescence (101). The mechanisms for 
these effects are not known. It is possible that BASP1 is exclusively cytoplasmic, and 
exerts its effects on gene expression by modulating activity or nuclear import of other 
transcription factors. Another possibility is that very low, undetectable levels of 
BASP1 are localised in the nucleus, and that this low level nuclear BASP1 affects 
transcription of certain genes directly.  
More experimentation could be conducted in order to further investigate the 
subcellular localisation of BASP1 in Ishikawa cells. One option is to subject the cells 
to immunofluorescence microscopy, probing for BASP1. This could detect possible 
low level BASP1 in the nucleus, if it is localised there. However, as previously shown, 
BASP1 wasn’t detectable by immunofluorescence in iPSCs but was shown to affect 
transcription via regulation of WT1 in iPSCs (101). It is possible that, even if 
immunoblotting and immuno-fluorescence fail to detect nuclear BASP1, BASP1 could 
be present at extremely low levels in the nucleus. Clear demonstration by ChIP that 
BASP1 localises to gene promoters would provide evidence for the nuclear 
localisation of BASP1. 
Previous MCF7 data showed BASP1 to reduce colony formation efficiency 
and to enhance the tamoxifen response (44). While similar tumour suppressor 
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activity was observed in Ishikawa cells, one difference between the cell types was 
that BASP1 seemed to have very little effect on the phenotype changes induced by 
tamoxifen in Ishikawa cells (fig.10-13). In both colony formation assays and growth 
assays, tamoxifen treatment had almost no significant effects on cell proliferation or 
colony formation. This is in contrast to previous observations in endometrial cells, in 
which tamoxifen has been shown to enhance cell growth and proliferation (107). It is 
possible that the concentration of tamoxifen used was too low or the incubation time 
with tamoxifen too short for the full effects to be observed. It is known that tamoxifen 
has many long term effects on endometrial cancer cells so it is also possible that the 
experiments used too short a time scale. Since qPCR of Ishikawa stable cell lines 
indicated that BASP1 did enhance the effects of Tamoxifen treatment on a subset of 
ERα target genes (fig.15), it is possible that with higher drug concentrations or drug 
incubation periods, the effects of BASP1 on phenotypic tamoxifen response in 















BASP1 as a transcriptional regulator 5.2 
The exact mechanisms by which BASP1 exerts tumour suppressor activity in 
breast cancer cells, acute myelogenous leukaemia cells, hepatocellular carcinoma 
cells and thyroid cancer cells are not known, but multiple studies have found that 
BASP1 possesses transcriptional coregulatory activities. BASP1 has been shown to 
interact with several major transcription factors including WT1, c-myc and ERα in a 
variety of cell types (17, 19, 44). In the BASP1-WT1 interaction, BASP1 binds to WT1 
and converts it from a transcriptional activator to a transcriptional repressor of WT1 
target genes. BASP1 does this by inducing the dissociation of CBP and the 
recruitment of HDAC1 to the WT1 transcriptional complex (27). In the case of 
BASP1-myc interaction, BASP1 has been shown to block myc induced changes in 
fibroblasts, but it is not known by what mechanism this occurs (19). More recently, 
the BASP1-ERα interaction has been investigated, and BASP1 has been shown, in 
breast cancer cells, to interact with ERα and localise directly at the promoters of ERα 
target genes. This interaction was found to have significant effects on the 
transcriptional activity of ERα in response to treatment with the ERα ligand 
Tamoxifen (44).  
In addition to the effects of BASP1 expression on Ishikawa cell proliferation, 
differing BASP1 expression was shown to result in changes in expression levels of a 
number of investigated genes (fig.14). PGR, Greb1, TFF1 and Rab31 expression 
levels were all significantly changed in response to differing levels of BASP1 
expression. These four genes are all known ERα target genes, implying that BASP1 
could be affecting ERα mediated transcriptional regulation. This activity of BASP1 as 
an ERα cofactor has already been observed in breast cancer cells (44) so it is 
possible that Ishikawa cells and breast cancer cells share similarities in BASP1 
function. However, the BASP1 dependent ERα target genes in breast cancer cells 
were different from those seen in Ishikawa cells. In MCF7 breast cancer cells, 
103 
 
BASP1 was not shown to regulate PGR, Greb1 or TFF1 and BASP1 did not affect 
tamoxifen induced expression changes of these genes (44). This indicates that, while 
BASP1 may similarly interact with ERα in the two cell types, the target genes and 
thus the effects of this interaction may be very different.  It should also be noted that 
the transcriptional effects of BASP1 in other cell types are highly complex and it is 
possible that these gene expression changes seen in ERα target genes in Ishikawa 
cells are secondary effects of other transcription factors.  
VDR was mostly unaffected by changes in BASP1 expression and tamoxifen 
treatment (fig.14-16). In one control Ishikawa cell line, VDR was significantly 
downregulated, but this effect was not reproduced in the other control cell line, nor 
was it seen in either the B-Ishikawa or sh-BASP1 Ishikawa cell lines. This suggested 
that the downregulation of VDR in V-Ishikawa cells could have been a false positive 
result. VDR is a known WT1 target gene but several studies of WT1 have uncovered 
cell type-specific effects on the genes that it regulates (108). This is in contrast to the 
regulation of VDR by WT1/BASP1 in K562 cells, podocyte cells and iPSCs (16, 17, 
101) but it further supports the hypothesis that the transcriptional effects produced by 
BASP1 could be occurring through ERα, as was previously seen in breast cancer 
cells (44). However, gene expression of more WT1 target genes in Ishikawa cells 
with varying BASP1 expression levels would be required before any conclusions 
about WT1 in Ishikawa cells could be drawn.  
In the BASP1-ERα interaction previously observed in MCF7s, BASP1 
localised directly at the promoters of ERα target genes. BASP1 expression was also 
shown to enhance the tamoxifen induced downregulation of a subset of ERα target 
genes, including XBP1 and Rab31 (44). In Ishikawa cells, tamoxifen treatment had 
no significant effects on XBP1 or Rab31 and altering BASP1 expression produced no 
significant change in this result. It is possible that, as mentioned above, tamoxifen 
concentration or incubation time was too low to produce a detectable effect on these 
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genes. However, since effects on other genes were detected, it is also possible that 
this was a result of the differences in BASP1 and ERα mechanisms of action 
between MCF7 breast cancer cells and Ishikawa cells. Differences between the cell 
types in BASP1 and ERα mechanisms of action are highly probable since BASP1 
has been shown to possess a complex range of transcriptional modulation activities 
in different cell types (17, 44, 101) and tamoxifen induced ER activity is known to be 
very different in Ishikawa cells from MCF7 cells (81). 
However, analysis of gene expression in Ishikawa cells by qPCR indicated 
that BASP1 enhances tamoxifen induced upregulation of a different subset of ERα 
target genes, PGR, Greb1 and TFF1, none of which were shown to be significantly 
affected by BASP1 in MCF7 cells. This suggests that BASP1 may modulate the 
tamoxifen response in Ishikawa cells by a similar mechanism to that which was seen 
in MCF7 cells, despite the opposing activities of ERα between the two cell types, but 
that this mechanism targets a different set of genes. In Ishikawa cells, BASP1 
overexpression was found not only to enhance the stimulation of PGR by TAM, but 
also to repress PGR expression in the absence of TAM. This indicates that the effect 
of BASP1 overexpression on PGR expression was reversed by tamoxifen treatment. 
These results together suggest a complex relationship between BASP1 and 
tamoxifen action in Ishikawa cells. In MCF7 cells BASP1 was not found to regulate 
PGR expression or to affect tamoxifen induced downregulation of PGR. Therefore, 
these results also highlight the differences in BASP1 functions between MCF7 breast 
cancer cells and Ishikawa endometrial cancer cells. It is possible that these 
differences in the functions of BASP1 between breast cancer cells and endometrial 
cancer cells could contribute to the differences in tamoxifen response between the 
two tissue types. 
The similarities in tumour suppressor activity and enhancement of tamoxifen 
induced gene expression changes by BASP1 between MCF7 cells and Ishikawa cells 
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raised the question, does BASP1 localise to ERα target genes in the nucleus of 
Ishikawa cells? ChIP analysis of BASP1 binding to the promoters of ERα target 
genes in Ishikawa cells produced insignificant results (fig.18). This was probably due 
to the requirement for further optimisation of the cross linking and sonication steps of 
the ChIP protocol (fig.17). While BASP1 binding was not significant, neither was ERα 
binding which was used as a positive control. The comparable detection of ERα and 
BASP1 at the promoters raises the possibility that BASP1 could be present at these 
promoters, but further optimisation and repeats of this ChIP are required before this 
conclusion can be made.  
In all, the results of this study indicate that BASP1 possesses tumour 
suppressor activity in Ishikawa cells and that this could be in part mediated by co-
regulation of ERα. In addition, BASP1 overexpression was shown to enhance 
tamoxifen induced gene expression changes of a subset of ERα target genes, 
suggesting similarities in the mechanism of action to that of MCF7 cells, but that 













5.3 Future directions 
 
5.3.1 Global RNA Sequencing 
One of the goals of future work investigating BASP1 in endometrial cancer 
cells is to perform RNA sequencing on the Ishikawa cells. Gene expression analysis 
of Ishikawa cells by qPCR indicated that BASP1 enhances the effects of tamoxifen 
on gene expression of a subset of ERα target genes (fig.15). This effect has been 
shown in both Ishikawa cells (fig.15) and previously in MCF7s (44). In Ishikawa cells, 
this effect was shown for PGR, Greb1 and TFF1 but not XBP1 or Rab31 in Ishikawa 
cells (fig.15) while the opposite was seen in MCF7 cells (44). The effects of BASP1 
expression in MCF7s was previously investigated by full RNA sequencing, in addition 
to qPCR analysis (44). Sequencing showed that 40% of tamoxifen induced gene 
expression changes in MCF7 cells were BASP1 dependent. RNA sequencing of 
Ishikawa cells would allow the effects of BASP1 expression on tamoxifen induced 
gene expression to be compared to those of MCF7 cells. The crossover and 
differences between the cell types could then be analysed to investigate the 
differences in BASP1 mechanisms in the two cell types. This data could reveal 
currently unknown roles of BASP1 in ERα activity in endometrial cancer cells and 
possibly, currently unknown roles of BASP1 in the oncogenic effect of tamoxifen in 
endometrial cancer cells. 
 
5.3.2 Other endometrial cell lines 
Another goal of future work will be to investigate the effects observed in this 
study in other endometrial cancer cell lines. The ERα-BASP1 interaction has been 
demonstrated in two breast cancer cell types: MCF7 cells and T47D cells. In order to 
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make any conclusions about the effects of BASP1 on ERα activity and the possible 
roles of BASP1 in the oncogenic effects of tamoxifen treatment on endometrial cells, 
the results will need to be reproduced in multiple endometrial cancer cell lines. Some 
endometrial cancer cell options for this include ECC1 and MFE-280 stable cell lines. 
Both lines, like Ishikawa cells, highly express ERα so BASP1 expression, localisation 
and effects on ER target genes could be investigated in these cell types. These cell 
lines would also provide a range of genotypes. Ishikawa cells have an epithelial-like 
morphology, while ECC1 cells maintain luminal cell morphology and MFE-280 cells 
have epithelial morphology. Investigation of these phenotypically diverse ER+ 
endometrial cancer cell lines could indicate whether the effects of BASP1 expression 
seen in this study are consistent across multiple endometrial cancer cell types. 
 
5.3.3 BASP1 G2A mutant 
One additional goal of future work will be to produce BASP1 G2A mutant 
Ishikawa cells in order to determine whether or not the effects seen in this study are 
dependent on myristoylation of BASP1. Conversion of glycine 2 in BASP1 to an 
alanine produces G2A mutant BASP1 which cannot be myristoylated. G2A BASP1 is 
therefore unable to interact with PIP2 and thus unable to bind to lipid membranes. It’s 
been shown that this myristoylation of BASP1 is required for transcriptional co-
suppression of WT1 target genes in embryonic kidney cells (12). Investigation of the 
effects of G2A BASP1 on tamoxifen induced gene expression changes could indicate 
whether myristoylation of BASP1 is required for the effects on ERα target genes 
seen in this study and provide a better idea of the mechanisms or localisation of 





5.3.4 Endometrial cancer tissue analysis 
Finally, another goal for future work will be to analyse endometrial cancer tissue by 
immunohistochemistry. This would allow comparison of BASP1 expression and 
localisation between endometrial cancer tissue and normal endometrial tissue. This 
was previously done in MCF7 cells and it was found that both ERα and BASP1 were 
upregulated in breast cancer tissue compared with the normal breast tissue (44). In 
addition, it would allow this comparison to be made between benign endometrial 
tumour tissue and endometrial cancer tissue. This would serve to investigate whether 
any changes in BASP1 expression and localisation are associated with tumour 
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